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CHAPTER 1  INTRODUCTION 
Parts of this chapter have been published in Yu, W., and Greenberg, M. L. (2016) 
Inositol depletion, GSK3 inhibition and bipolar disorder. Future Neurology. (In press)  
 Bipolar disorder (BD) is a severe psychiatric illness affecting about 2% of the 
world population. BD patients suffer from recurring cycles of mania and depression, 
which greatly hamper interpersonal relationships and career success. The mortality rate 
of BD patients is 15-20% higher than that of the general population (1). Approximately 
15% of BD patients commit suicide (2).  Lithium and valproic acid (VPA) are among the 
most widely used and best-studied mood stabilizers (3,4). However, these and other 
major anti-bipolar therapies cause serious side-effects and have limited efficacy (5). 
Thus, there is a great demand for more effective anti-bipolar drugs. Efforts to develop 
new treatments for BD are hampered by the lack of knowledge of the therapeutic 
mechanisms of the current drugs. Several hypotheses have been proposed to elucidate 
the mechanisms underlying the mood-stabilizing effects of the drugs. In this review, we 
focus on the controversies and connections characterizing two current hypotheses of 
the therapeutic mechanisms of lithium and VPA – inositol depletion and GSK3 inhibition 
– and suggest that the two mechanisms may be related. 
1. Inositol depletion hypothesis 
1.1. Inositol metabolism  
 Myo-inositol is the precursor of all inositol lipids and inositol phosphates. 
Eukaryotic cells obtain inositol by three routes. Inositol is taken up from the surrounding 
environment by inositol transporters (6,7). In the absence of exogenous inositol, it is 
synthesized de novo from glucose-6-phosphate (G6P) in a two-step reaction (Fig. 1-1). 
G6P is first converted to inositol-3-phosphate by myo-inositol-3-phosphate synthase 
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(MIPS), which is encoded by ISYNA1 and INO1 in human and yeast cells, respectively 
(8-11). The second step is the conversion of inositol-3-phosphate to inositol, which is 
catalyzed by inositol monophosphatase (IMPase) (12). Inositol is also obtained by 
recycling inositol phosphates (13). The levels of inositol in brain are significantly higher 
than in blood and other tissues (14), suggesting that high levels of inositol are critical for 
normal brain function. Although brain cells can take up inositol from the blood, uptake is 
slowed by the blood-brain barrier (15,16), suggesting that inositol de novo synthesis and 
the recycling of inositol phosphates are the main sources of inositol in brain (17).  
 Inositol is an essential substrate for the synthesis of phosphatidylinositol (PI), 
from which are derived the phosphatidylinositol phosphates. Seven known 
phosphatidylinositol phosphates are derived from PI, including PI(3)P, PI(4)P, PI(5)P, 
PI(3,4)P2, PI(3,5)P2, PI(4,5)P2 and PI(3,4,5)P3 (18). Phosphoinositides are signaling 
molecules that mediate cell growth, proliferation, apoptosis, insulin action and many 
other cellular events (19). It is not surprising, therefore, that perturbation of 
phosphoinositide metabolism is associated with many disorders (18). Upon receptor 
mediated activation of phospholipase C (PLC), PI(4,5)P2 is cleaved to form inositol-
1,4,5-triphosphates (IP3) and 1,2-diacylglycerol (DAG) (20). IP3 can be recycled to myo-
inositol by a series of dephosphorylations catalyzed by inositol polyphosphate 
phosphatase and IMPase (21). Alternatively, IP3 can be phosphorylated sequentially to 
form IP4, IP5, and IP6 by inositol phosphate kinases (13,21). These molecules convey 
signals for a variety of cellular processes, although the functions of inositol phosphates 
are not fully understood (22,23). Inositol phosphates can be further phosphorylated on 
existing phosphate groups to form pyrophosphates (24,25), whose functions are 
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Figure 1-1. The inositol de novo synthesis pathway. Inositol is synthesized in a two-
step reaction. Glucose 6-phosphate (G-6-P) is converted to inositol-3-phosphate (I-3-P) 
by myo-inositol-3-phosphate synthase (MIPS), which is the rate-limiting enzyme of 
inositol synthesis. At the second step, I-3-P is dephosphorylated by inositol 
monophosphatase (IMPase) to generate myo-inositol.  
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involved in the regulation of gene expression, vesicular tracking and DNA repair (26-28).  
 Many inositol-containing molecules function as metabolic sensors that regulate 
neuronal function and neurotransmission (13). For example, IP3 is a second messenger 
that activates the release of calcium from cellular storage (20). Calcium signaling 
regulates neuronal differentiation, apoptosis, and exocytosis (29). Many receptors in the 
central nervous system activate PLC-dependent cleavage of PIP2 and increase 
IP3/calcium release (30). Perturbation of intracellular inositol metabolism has been 
associated with bipolar disorder, Alzheimer’s disease, diabetes and cancer (18). 
Therefore, maintaining stable inositol homeostasis is critical for normal cellular function 
(13,31).  
1.2. Altered inositol levels in BD 
 A correlation has been observed between BD and altered levels of inositol in 
brain. Altered myo-inositol and phosphoinositide levels have been observed in brains of 
living BD patients using magnetic resonance spectroscopy (32-34). Higher myo-inositol 
signals were detected in brains of BD patients during the manic phase (35). Conversely, 
significantly lower levels of myo-inositol were identified in the frontal cortex of BD 
patients during the depressive phase (36). Frontal cortex samples from postmortem BD 
patients also exhibited decreased myo-inositol levels (37). Furthermore, myo-inositol 
levels were reduced in cerebrospinal fluid obtained from affective depression patients 
(38). Interestingly, dietary supplementation of inositol (12g/day for 4 weeks in one study) 
led to significant efficacy for the treatment of depression (39,40).  Inositol also alleviated 
depression in animal models (41,42). These studies suggest that abnormal brain inositol 
levels may play a role in mood disorders. 
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1.3. VPA and lithium inhibit inositol synthesis  
 Despite the fact that lithium has been used for more than 60 years for the 
treatment of BD, the therapeutic mechanism of the drug remains unknown (4).  Similarly, 
the mechanism underlying VPA efficacy is not understood (43).  Lithium was shown to 
be an uncompetitive inhibitor of IMPase, which catalyzes the conversion of inositol-3-
phosphate to myo-inositol (44-46). Berridge and co-workers hypothesized that inhibition 
of inositol synthesis by lithium leads to decreased PI synthesis and subsequent 
attenuation of PI signaling (46). These pivotal studies laid the foundation for the inositol 
depletion hypothesis as a potential therapeutic mechanism of action of lithium. In 
support of the hypothesis, studies in animal models suggested that the mood-stabilizing 
effect of lithium is correlated with inhibition of inositol synthesis. Lithium reduced myo-
inositol levels in rat brain (47). Inositol levels in rat cerebral cortex decreased 30% by 6 
h after lithium injection, and the reduction of inositol persisted for 24 h. In addition, VPA 
and lithium treatment led to a reduced intracellular concentration of IP3 (17,48,49). 
Lithium-induced inositol depletion resulted in reduction of PIP3 (49,50). Inositol deficient 
diet augmented the effect of lithium in behavioral studies (51). These studies support 
the hypothesis that mood-stabilizing drugs suppress PI signaling via affecting inositol 
metabolism. Inositol depletion also affects other cellular functions that are associated 
with psychiatric illness. Inositol depletion and VPA treatment altered PI(3,5)P2 
homeostasis and perturbed vacuolar ATPase function in yeast; while similar studies 
have not yet been carried out in mammalian cells, these functions are important for 
neurotransmission (52). VPA and lithium prompted synapse formation between 
hippocampal neurons, which could be reversed by pretreatment with exogenous inositol 
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(53). Inositol depletion resulted in defective craniofacial development and brain function 
in a mouse model (54).   
 Understanding how inositol synthesis is regulated is of obvious importance to 
elucidating drug-related mechanisms of inositol depletion.  Surprisingly, regulation of 
inositol synthesis in mammalian cells has not been well-studied.  In contrast, inositol 
synthesis has been well characterized in the yeast Saccharomyces cerevisiae (55-57). 
In this yeast, both lithium and VPA were shown to inhibit inositol synthesis.  Lithium 
reduces intracellular inositol levels in yeast, as in human cells, by inhibiting inositol 
monophosphatase (58,59).  Interestingly, VPA was also shown to perturb inositol 
metabolism in yeast (59). VPA depletes inositol by a different mechanism from that of 
lithium. Vaden et al. first discovered that VPA causes decreased levels of intracellular 
inositol-3-phosphate and inositol in yeast (59), consistent with inhibition of MIPS, which 
catalyzes the synthesis of inositol-3-phosphate from G6P.  Indeed, VPA was shown to 
cause a 35% decrease of MIPS enzymatic activity in vivo at a drug concentration used 
therapeutically (0.6 mM). Subsequent studies showed that VPA also inhibited human 
MIPS expressed in yeast cells (60). In contrast to direct inhibition of IMPase by lithium, 
inhibition of MIPS activity is indirect and not observed in vitro. Indirect inhibition of MIPS 
by VPA is also observed in human brain (61). Consistent with inositol starvation, chronic 
VPA treatment significantly decreased PI synthesis and increased CDP-DAG levels in 
yeast (62).  
 Both yeast and human MIPS are phosphoproteins, and phosphorylation of MIPS 
has been shown to regulate activity of both enzymes (63,64). Three phosphorylation 
sites were identified and mapped to Ser-184, Ser-296 and Ser-374 in yeast MIPS and 
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the corresponding sites Ser-177, Ser-279, and Ser-357 in human MIPS. VPA was 
shown to increase phosphorylation of yeast MIPS (64).  The simultaneous mutation of 
both Ser-184 and Ser-374 to Ala resulted in a four-fold increase in MIPS enzyme 
activity and decreased sensitivity of cells to VPA (64). Although inhibition of MIPS by 
VPA is indirect, VPA directly or indirectly affects protein kinase A (PKA), AKT (also 
known as protein kinase B), glycogen synthase kinase-3 (GSK3), and protein kinase C 
(PKC) signaling pathways (65-67). Therefore, it is plausible that inhibition of MIPS by 
VPA may be an indirect outcome of affecting these kinases. 
 VPA-mediated perturbation of inositol metabolism was also reported in animal 
studies. VPA and lithium caused similar levels of inositol depletion in rat brain (68). 
Acute VPA treatment reduced inositol levels in mouse frontal cortex tissue (61). Inositol 
reversed the inhibitory effects of VPA and lithium on the collapse of sensory neuron 
growth cones and the increase in growth cone area in rat ganglia cells (17). These 
studies indicate that inositol depletion is a common outcome of structurally disparate 
anti-bipolar drugs.  
1.4. Inositol depletion and PKC  
 PKC, a target of lithium and VPA that is associated with BD, is affected by 
inositol. PKC comprises a family of serine/threonine kinases that are ubiquitous in 
mammalian tissues (69). It is highly enriched in brain, where its activity affects 
numerous cellular processes, including neurotransmission, secretion, cell proliferation 
and localization of extracellular receptors (70). Several PKC isoforms are activated by 
DAG, the signaling molecule generated from the cleavage of PIP2 (71). Numerous 
studies associate PKC with the pathophysiology and treatment of BD. Serotonin-
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induced PKC translocation was altered in platelets obtained from BD patients during the 
manic phase (72). The ratio of membrane-bound to cytosolic PKC activities was shown 
to be elevated in BD patients and decreased after lithium treatment (72). Alteration of 
PKC levels and activities were also reported in a study of postmortem BD brain (73). 
Furthermore, a genome-wide association study identified diacylglycerol kinase η (DGKH) 
as a risk gene in the etiology of BD (74). DGKH catalyzes the metabolism of DAG to 
phosphatidic acid. Because DAG is a necessary cofactor for many isoforms of PKC, 
DGKH is thought to attenuate PKC (75). A study of post-mortem brain tissue 
demonstrated increased expression of DGKH in the prefrontal cortex of BD patients (76), 
suggesting that altered expression of DGKH is involved in the pathogenesis of BD. 
Taken together, these findings suggest a close association between perturbation of the 
PKC pathway and BD.  
 Interestingly, both lithium and VPA were shown to reduce PKC levels (77). Rats 
chronically treated with lithium exhibited a decrease in membrane-associated PKC α in 
hippocampus (78). The co-administration of myo-inositol reversed the decrease in PKC 
α and ε levels in hippocampus samples of rats treated with lithium (79). Chronic 
treatment with VPA also reduced levels of PKC α and ε in rat cells (80). Tamoxifen, a 
strong inhibitor of PKC widely used for the treatment of breast cancer, exhibited 
significant efficacy in reducing manic symptoms, although it was not effective for BD 
patients during the depression phase (81).  
 In summary, perturbation of PKC activity is closely associated with the etiology of 
BD. It is tempting to speculate that down-regulation of PKC by lithium and VPA induces 
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inositol depletion, which may exert therapeutic effects by altering downstream signaling 
pathways. 
1.5. Discrepancies of the inositol depletion hypothesis 
 Some studies do not support the inositol depletion hypothesis. First, reduction of 
mouse brain inositol levels alone did not lead to mood stabilization (82). Mice 
heterozygous for the null allele of the myo-inositol transporter 1 (SMIT1) gene exhibited 
a 33-37% decrease in inositol in brain tissue, which was greater than the 22-25% 
decrease observed in lithium treated mouse brain. However, only lithium treated mice, 
but not SMIT+/- mice, exhibited a significant decrease in immobility in the forced swim 
test (82,83). A second argument against the inositol depletion hypothesis is that inositol 
depletion does not necessarily lead to decreased PI signaling. Phosphatidylinositol 
levels were compared in WT and SMIT -/- mouse fetal brain. Although SMIT -/- mice 
exhibited a 92% decrease in intracellular inositol, phosphatidylinositol levels were not 
significantly changed (84). However, it is possible that 8% of WT levels of inositol 
remaining in SMIT -/- mice may be sufficient to accommodate normal PI signaling. Third, 
it is not clear how inositol depletion can effectively treat both mania and depression. 
Studies by Cheng et al. suggested a mechanism whereby VPA and other mood 
stabilizing drugs may exert their dual action by maintaining stable PI signaling (85). 
Inositol depletion may attenuate PI signaling in manic patients, while VPA-induced 
inhibition of prolyl oligopeptidase may increase PI signaling in depressed patients (85). 
 In summary, while many common outcomes of anti-bipolar drugs are well 
explained by inositol depletion, some studies are not consistent with the hypothesis.  
2. GSK3 inhibition hypothesis 
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2.1. GSK3 activation is inhibited by lithium 
 In 1996, Klein and Melton reported that lithium is an inhibitor of GSK3β in 
Xenopus (86). Subsequent studies showed that lithium inhibited GSK3β in Drosophila, 
cultured mammalian cells, and rat brain (87-93). Lithium can directly inhibit GSK3 by 
competing with the co-factor magnesium for binding to the enzyme (94), and/or by 
prompting inhibitory serine phosphorylation through multiple mechanisms, including 
PKA, phosphatidylinositol-3 kinase (PI3K)/AKT, PKC pathways, and autoregulation of 
GSK3 (95-98). These findings led to the hypothesis that GSK3 inhibition may be the 
therapeutic mechanism of mood-stabilizing drugs.  
 Glycogen synthase kinase-3 (GSK3) was first identified as a protein kinase that 
phosphorylates and inactivates glycogen synthase (99,100). As a serine/threonine 
kinase, GSK3 is involved in the regulation of many cellular functions that affect cell fate 
determination, cell survival, and signal transduction (101-103). Two isoforms of GSK3 
exist in mammalian cells, GSK3α and GSK3β (104,105). These isoforms exhibit 98% 
identity in the amino acid sequences of their kinase domains (105). GSK3 activity is 
regulated by the PI3K/AKT pathway, which phosphorylates GSK3α and GSK3β on 
serine-21 and serine-9, respectively, inhibiting their enzymatic activities (106,107). 
GSK3β, the predominant form in brain, regulates more than 40 proteins in many cell 
signaling pathways, some of which play a role in BD as well as Alzheimer’s disease and 
cancer (102,103,108,109).  
 To determine if GSK3β inhibition may account for the therapeutic effect of mood-
stabilizing drugs, behavioral efficacies of reduction of intracellular GSK3β and lithium 
treatment were compared (110). Mice chronically treated with lithium exhibited 
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significantly decreased immobility in the forced swim test, a positive anti-depressive 
effect (111). Interestingly, mice with heterozygous deletion of GSK3β, in which GSK3β 
levels are significantly decreased, also exhibited decreased immobility time in the forced 
swim test, as well as other behavior changes similar to those seen in lithium treated 
mice (110). Behavior changes observed in lithium treated and GSK3β +/- mice were 
reversed by overexpression of GSK3β, indicating that GSK3β is a target of lithium (112). 
Consistent with inhibition of GSK3 as a therapeutic mechanism, mood-stabilizing effects 
were reported for many GSK3 inhibitors. Rodents treated with GSK3 inhibitors AR-
A014418 and L803–mts exhibited reduced immobility time in the forced swim test (113-
115). In addition to the anti-depressive effect, GSK3 inhibitors also reduced manic 
behaviors in animal studies. A variety of GSK3 inhibitors reduced hyperactivity in mouse 
models of mania (114,116). In addition, mice with heterozygous deletion of GSK3β also 
exhibited attenuated amphetamine-induced hyperactivity (116). These findings suggest 
that reduced GSK3 activity contributes to alleviation of manic behavior in animal models.  
2.2. Inhibition of GSK3 by VPA 
 VPA was shown to inhibit GSK3β in some (117-120) but not all studies (121). 
Chen and co-workers demonstrated that VPA inhibits GSK3 in both in vivo and in vitro 
assays (117). The activities of GSK3α and GSK3β, assayed in vitro by incorporation of 
32P into cAMP response element-binding protein (CREB) phosphopeptides, decreased 
in the presence of VPA in a concentration dependent manner.  In vivo assays using β-
catenin degradation as an indicator of GSK3β activity showed significant increases in β-
catenin levels in cytosol and nucleus of VPA-treated neuronal cells, consistent with 
GSK3 inhibition (117). Phosphorylation of tau protein by human GSK3β was also 
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decreased in the presence of VPA in a concentration dependent manner (119). 
Furthermore, VPA treatment inhibited phosphorylation of microtubule-associated protein 
1B (Map-1B) by GSK3β in vivo in neuronal cells (118). However, in contrast to the 
finding of Chen and co-workers, VPA did not inhibit GSK3β in vitro in the study of Hall 
and co-workers, suggesting that inhibition of GSK3β by VPA may be indirect (118). The 
inhibitory effect of VPA on GSK3β was further supported by the finding of increased 
levels of GSK3β serine-9 phosphorylation in VPA-treated human neuroblastoma cells 
(122). In addition, similar to lithium, VPA exerted behavioral effects as a result of 
disrupting the AKT/GSK3 signaling pathway (123). 
 While the findings described above suggest that VPA inhibits GSK3β, this 
outcome in not universally supported. In the report of Phiel and co-workers, VPA did not 
affect the phosphorylation of tau protein by GSK3β in neuronal cells or the in vitro 
phosphorylation of glycogen synthase peptide-2 (121). In addition, increased β-catenin 
levels were observed in dorsal root ganglia cultures treated with lithium but not VPA 
(17). Similar results were obtained in other studies (124,125). The variety of model 
systems and methodologies used in these studies likely contributes to the discrepancy 
in results, and further investigation is necessary to understand the effect of VPA on 
GSK3. 
2.3. HDAC inhibition and GSK3 activity  
 Therapeutic concentrations of VPA have been shown to inhibit histone 
deacetylase (HDAC) (126) (127,128). Interestingly, HDAC inhibitors exhibit anti-
depressive effects in mouse models of depression (129,130). HDAC inhibition greatly 
affects the transcription profile and alters cellular signaling, consequences that could 
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potentially account for the therapeutic effects of VPA (131). For example, long-term 
treatment with the HDAC inhibitor Cpd-60 led to significantly increased levels of Sgk1 
expression in mouse brain (130).  Up-regulation of Sgk1 was also reported in rodents 
treated with lithium and other anti-depressants (132,133). Sgk1 encodes a protein 
kinase that phosphorylates and inhibits GSK3β (134). As discussed previously, the 
activity of GSK3 is negatively regulated by the AKT signaling pathway. VPA increased 
the activation-associated phosphorylation of Akt and the inhibition-associated 
phosphorylation of GSK3β (122). Two other HDAC inhibitors, TSA and sodium butyrate, 
also mimicked the effect of VPA in activating Akt and inhibiting GSK3β, suggesting that 
HDAC inhibition promotes GSK3β inhibition via the AKT pathway (122). Although the 
discrepancy remains as to whether VPA directly affects GSK3 activity, as discussed 
above, these findings suggest that VPA indirectly inhibits GSK3β by inhibiting HDAC, 
which may underlie the anti-depressant effects of the drug.  
2.4. Neurotrophic effects of GSK3 inhibition 
 Many studies have reported a loss of neuronal and glial cells in the brains of BD 
patients (135-138), possibly due to increased apoptosis (139). GSK3 is a pro-apoptotic 
enzyme, the activation of which facilitates apoptosis (140,141). Therefore, GSK3 
inhibition may exert its neurotrophic and anti-bipolar effects by decreasing apoptosis of 
neuronal cells in the brain. The reduction of intracellular GSK3β levels was shown to 
protect neurons from amyloid-β induced neurotoxicity (142), while overexpression of 
GSK3β induced caspase-3 dependent apoptosis in mouse neuronal cells (143). 
Granulocyte-colony stimulating factor (G-CSF) is a neuroprotective growth factor that 
antagonizes apoptosis by inhibiting GSK3β (144). The connection between altered 
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GSK3 activity and apoptosis was further supported by the finding that several selective 
GSK3 inhibitors and anti-bipolar drugs, including VPA and lithium, also provided 
significant protection from apoptotic cell death (67,145-147).  In a mouse model, VPA 
was shown to exert an anti-apoptotic effect by up-regulating B-cell lymphoma 2 (Bcl-2) 
expression (148). VPA and lithium increased intracellular Bcl-2 levels in human 
neuronal cells (149). VPA also inhibited apoptosis in human endothelial cells by 
preventing Bcl-2 ubiquitination (150). Furthermore, lithium prompted neural precursor 
cell proliferation via GSK-3β-NF-AT (nuclear factor of activated T cells) signaling (151). 
GSK3 inhibition exhibited neuroprotective effects against excitotoxicity (152). These 
studies suggest that VPA and lithium may exert their therapeutic effects by promoting 
survival and proliferation of neuronal cells as a consequence of GSK3 inhibition.  
 In addition to promoting anti-apoptotic signaling, inhibition of GSK3β leads to 
activation of the Wnt pathway and up-regulation of β-catenin (153-155). As a 
transcription factor, β-catenin plays an important role in regulating neuronal connectivity, 
which is critical for diverse neuronal functions (156). Some evidence suggests that 
increased intracellular β-catenin is a potential therapeutic strategy of BD treatment. 
L803-mts, a selective GSK3β inhibitor with anti-depressive efficacy, caused elevated β-
catenin expression in mouse hippocampus (113). Overexpression of β-catenin in mouse 
brain and lithium treatment induced similar behavior changes, including decreased 
immobility time in the forced swim test (157). Furthermore, overexpression of β-catenin 
inhibited amphetamine-induced hyperlocomotion, mimicking the anti-manic effect of 
lithium. A recent study using induced pluripotent stem cell (iPSC) lines derived from BD 
patients indicated abnormal neurogenesis and expression of genes that are critical for 
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Wnt signaling (158). The proliferation defect in BD-iPSC cells was rescued by GSK3 
inhibition. Together, these findings suggest that the therapeutic efficacy of GSK3β 
inhibition in BD may occur by upregulating β-catenin. Targeting Wnt/β-catenin signaling 
may be a promising strategy for BD treatment. 
 In summary, GSK3 may play a pivotal role in the therapeutic mechanisms of 
bipolar disorder therapy. Altered GSK3 activity and protein levels were observed in BD 
patients. Decreasing GSK3 by genetic ablation or treatment with inhibitors mimics the 
mood-stabilizing effect of anti-bipolar drugs in animal behavior studies. In addition, 
several studies reported that VPA inhibits GSK3 enzymatic activity. These findings 
suggest that GSK3 inhibition, similar to inositol depletion, is a common effect of 
structurally disparate mood-stabilizing drugs.  
3. A unified model of inositol depletion and GSK3 inhibition 
 While inositol depletion and GSK3 inhibition may appear to be unrelated, we 
suggest that they may constitute components of a single mechanism. Studies have 
shown that GSK3 is required for optimal inositol biosynthesis in yeast (159). Yeast cells 
lacking GSK3 (gsk3△ cells) exhibit multiple features of inositol depletion: intracellular 
inositol levels in gsk3△ are 70% lower than in WT cells; the growth rate of gsk3△ cells in 
I- medium is significantly slower than that of WT cells; and the mutant exhibits 
decreased MIPS enzymatic activity (159). These findings indicate that GSK3 is required 
for optimal inositol homeostasis in yeast. As discussed above, MIPS activity is regulated 
by phosphorylation. Interestingly, a potential GSK3 phosphorylation site has been 
identified in yeast MIPS (Fig. 1-2). Mutation of this residue results in alteration of MIPS 
enzymatic activity, suggesting a potential regulatory mechanism of MIPS by GSK3 
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Figure 1-2. A potential GSK3 phosphorylation site in MIPS. Both human and yeast 
MIPS contain a potential GSK3 phosphorylation site (serine-279 of human MIPS and 
serine-296 of yeast MIPS) within a six-amino acid region of identity (64).  
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through phosphorylation (64). Strikingly, a sequence identical to the putative yeast 
GSK3 phosphorylation site is present in human MIPS (64). Mutation of this site in the 
human enzyme affected MIPS activity similar to the yeast mutant enzyme. We 
speculate that regulation of MIPS activity by phosphorylation of this site may be a 
conserved mechanism of regulation of inositol synthesis. Interestingly, inositol synthesis 
in neuronal cells was shown to affect GSK3 activity. Knockdown of the ISYNA1 gene, 
which encodes MIPS in mammalian cells, led to inactivation of GSK3α by increasing 
inhibitory phosphorylation of Serine-21 (160), suggesting that GSK3 and inositol 
synthesis may be coordinately regulated. 
 GSK3 may also regulate inositol synthesis by affecting metabolism of glucose 6-
phosphate (G6P), which is the substrate for inositol de novo synthesis. GSK3 controls 
the conversion of glucose to glycogen by regulating glycogen synthase activity (99). The 
inhibition of GSK3 in hepatic cells reduces expression of glucose-6-phosphatase and 
phosphoenolpyruvate carboxykinase, which regulate gluconeogenesis (161). In addition, 
expression of phosphoglucomutase 2 (PGM2), which catalyzes the interconversion of 
glucose-1-phosphate and glucose-6-phosphate (162), requires GSK3 activity (163). 
Interestingly, lithium inhibits PGM2 (164), whereby it may also affect intracellular G6P 
production. These findings suggest that GSK3 may regulate inositol synthesis by 
controlling the availability of G6P. It will be of great importance to determine if VPA, 
lithium and GSK3 inhibition affect the rate of glucose uptake and G6P production.   
The model shown in Fig. 1-3 unifies both inositol depletion and GSK3 inhibition in 
the following hypothesis. VPA induces inositol depletion by decreasing MIPS activity 
through inhibition of GSK3. As a major component of intracellular signaling molecules, 
18 
 
 
 
Figure 1-3. Model: Dual effects of VPA and lithium on inositol depletion and GSK3 
inhibition contribute to mood stabilization. GSK3 is required for optimal de novo 
synthesis of inositol in yeast. VPA (upper panel) indirectly inhibits MIPS, the rate limiting 
enzyme of inositol de novo synthesis, possibly by inhibiting GSK3, thereby reducing 
intracellular inositol. Lithium (lower panel) depletes inositol by inhibiting IMPase, and 
inhibits GSK3 by multiple mechanisms. In addition to inhibition of MIPS activity, GSK3 
inhibition may also affect metabolism of G6P, the substrate for inositol de novo 
synthesis. Inositol depletion leads to perturbation of numerous cellular functions, some 
of which are associated with mood stabilization. Inhibition of GSK3 affects cells in 
numerous ways, some of which are neurotrophic and may contribute to mood 
stabilization. 
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inositol is involved in the regulation of PI synthesis, protein secretion and many other 
cellular functions (18,19,165). Alteration of inositol metabolism affects expression of 
hundreds of genes and causes numerous cellular consequences (31,166), among 
which are those that may lead to mood stabilization. VPA-induced GSK3 inhibition also 
exerts neurotrophic effects by reducing apoptosis of neuronal cells through up-
regulation of anti-apoptotic factors, and by up-regulation of β-catenin. Lithium also 
causes dual effects of GSK3 inhibition as well as inositol depletion by inhibition of 
IMPase. The inter-relationship between inositol depletion and GSK3 inhibition may 
contribute to the therapeutic effects of VPA and lithium. 
4. Conclusion 
 Although the therapeutic mechanisms of VPA and lithium are not understood, 
both inositol depletion and GSK3 inhibition are common outcomes of treatments by 
these structurally dissimilar drugs and may play a role in their therapeutic effects.  We 
speculate that VPA- and lithium-induced GSK3 inhibition may inhibit MIPS enzymatic 
activity by mediating the inhibitory phosphorylation of MIPS, the rate limiting enzyme of 
de novo inositol synthesis, resulting in depletion of intracellular inositol.   
Project outline 
 The goal of the studies presented in this thesis was to elucidate new 
mechanisms of regulation of inositol metabolism, and to understand the physiological 
effects of inositol-depleting compounds. Three independent projects focusing on the 
regulation of inositol synthesis are described in the following chapters. The 
interrelationships of these projects are demonstrated in Figure 1-4. 
 The studies in Chapter 2 demonstrate that Mck1 is the yeast GSK3β homolog 
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Figure 1-4. Project outline. Chapter 2 demonstrates that Mck1 regulates the rate of 
inositol synthesis and mediates VPA-induced MIPS inhibition. Chapter 3 characterizes 
IP6K1 as a novel negative regulator of inositol synthesis in mammalian cells. IP6K1 
inhibits expression of the mammalian MIPS-encoding gene Isyna1 (mIno1). Studies in 
Chapter 4 show that VPA depletes intracellular G-6-P, possibly by inhibiting expression 
of hexose transporter genes. VPA induces Mig1 nuclear translocation, which represses 
hexose transporter gene expression. 
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required for optimal synthesis of inositol. mck1∆ exhibited multiple features of inositol 
depletion, which could be rescued by supplementation of inositol. Intracellular inositol 
levels and MIPS activity were also decreased in mck1∆ cells. VPA requires Mck1 to 
inhibit MIPS enzymatic activity. Taken together, Mck1 mediates VPA-induced MIPS 
inhibition, which thereby leads to inositol depletion.  
 In Chapter 3, I identified and characterized IP6K1 as a novel regulator of inositol 
synthesis in mammalian cells. Ip6k1 ablation led to profound changes in DNA 
methylation and expression of mIno1, which encodes the rate-limiting enzyme inositol- 
3-phosphate synthase. Interestingly, IP6K1 preferentially bound to the phospholipid 
phosphatidic acid, and this binding was required for IP6K1 nuclear localization and the 
regulation of mINO1 transcription. This is the first demonstration of IP6K1 as a novel 
negative regulator of inositol synthesis in mammalian cells.  
 Chapter 4 describes the effect of VPA on G-6-P metabolism and expression of 
hexose transporter genes. This study demonstrated that chronic VPA treatment 
depletes intracellular G-6-P. VPA also inhibits expression of HXT2, HXT3, HXT4, and 
HXT4, which encode glucose transporters, possibly by activating Mig1-mediated 
transcription repression. These findings suggest that VPA depletes intracellular G-6-P, 
at least partially, by decreasing glucose uptake. Therefore, VPA-induced perturbation of 
G-6-P metabolism may affect downstream pathways, including inositol synthesis and 
glycolysis.  
 While this dissertation describes exciting findings on the regulation of inositol 
synthesis, many interesting questions remain. These questions are presented in 
Chapter 5 as topics for future study.  
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CHAPTER 2  MCK1 REGULATES THE RATE OF INOSITOL SYNTHESIS BY 
INCREASING MYO-INOSITOL-3-PHOSPHATE SYNTHASE (MIPS) ACTIVITY IN 
SACCHAROMYCES CEREVISIAE  
INTRODUCTION 
 Myo-inositol is the precursor of all inositol compounds, including 
phosphoinositides, inositol phosphates, inositol sphingolipids, and 
glycosylphosphatidylinositols. Inositol compounds are critical for many key cellular 
processes (20,27,167,168), and are essential for the viability of eukaryotes. The pivotal 
role of inositol is underscored by the link between perturbation of inositol metabolism 
and human neurological disorders(18). In addition, inositol depletion was proposed as 
the therapeutic effect of valproic acid (VPA) and lithium. Therefore, elucidating how 
inositol synthesis is regulated is of obvious importance to understanding cell function 
and the pathologies underlying many illnesses.  
 The de novo synthesis of inositol has been well characterized in the yeast 
Saccharomyces cerevisiae. Inositol is synthesized de novo from glucose-6-phosphate 
(G-6-P) in a two-step reaction. G-6-P is first converted to inositol-3-phosphate by the 
rate-limiting enzyme myo-inositol-3-phosphate synthase (MIPS), which is encoded by 
INO1 (8-10,169,170). Then inositol-3-phosphate is dephosphorylated to myo-inositol 
(12). Inositol synthesis is tightly regulated at the level of transcription of INO1 in 
response to extracellular inositol levels (171,172). Furthermore, both yeast and human 
MIPS are phosphoproteins, whose activities are regulated by phosphorylation (63,64).  
Yeast cells treated with VPA at concentrations used therapeutically exhibited decreased 
MIPS activity (59), and the inhibition of MIPS activity was indirect and not observed in 
vitro (60). VPA induced MIPS inhibition was also reported in human brain tissue (61). 
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VPA has also been shown to increase phosphorylation of MIPS (64). Therefore, VPA 
possibly inhibits MIPS via an as yet unidentified kinase.  
 A clue to the mechanism underlying VPA-induced MIPS inhibition came from the 
finding that yeast GSK3 homologs are required for optimal de novo synthesis of inositol. 
Yeast gsk3∆ cells exhibited multiple features of inositol depletion, including decreased 
growth in I- media, decreased intracellular inositol levels, and increased sensitivity to the 
inositol-depleting drug VPA (159).  As a serine/threonine kinase, GSK3 is involved in 
the regulation of many cellular functions (101-103). Two isoforms of GSK3 exist in 
mammalian cells, GSK3α and GSK3β (104,105). These isoforms exhibit 98% identity in 
the amino acid sequences of their kinase domains (105). GSK3β, the predominant form 
in the brain, regulates more than 40 proteins in many cell signaling pathways, some of 
which play a role in BD as well as Alzheimer’s disease and cancer (102,103,108,109). 
The inhibition of GSK3β activity contributes to alleviation of BD symptoms in animal 
models (110,113-116). Interestingly, a potential GSK3 phosphorylation site was 
identified in both yeast and human MIPS, suggesting that GSK3 regulates MIPS 
phosphorylation (64). Furthermore, VPA has been shown to inhibit GSK3 in several 
studies (117-120). Therefore, GSK3 possibly mediates VPA-induced MIPS inhibition, 
which leads to inositol depletion. 
 Four genes encode yeast GSK3 homologs, MCK1, MDS1, MRK1 and YGK3 
(173). The yeast gsk3∆ strain is a quadruple null mutant in which all four genes are 
knocked out. The functions of these genes are not well understood. More importantly, it 
is not clear which gene is involved in the regulation of yeast inositol synthesis.  
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 In this report, we demonstrate that MCK1 encodes the yeast GSK3 homolog 
required for the optimal synthesis of inositol. mck1∆ cells exhibited decreased growth in 
the presence of VPA, which was rescued by the supplementation of inositol. The 
intracellular inositol levels, MIPS activity, and in vivo rate of inositol synthesis were 
decreased in mck1∆ cells. VPA treatment did not reduce MIPS activity in mck1∆ cells, 
indicating that Mck1 mediates VPA-induced MIPS inhibition. Interestingly, the triple-null 
mutant (mds∆1mrk1∆ygk3∆) did not exhibit any feature of inositol depletion, suggesting 
that inositol depletion observed in gsk3∆ cells is due to ablation of the MCK1 gene. This 
study demonstrates for the first time that the yeast GSK3 homolog Mck1 regulates 
inositol synthesis by increasing MIPS activity. 
MATERIALS AND METHODS 
Yeast strains 
 All strains used in this study were in the W303 background. The WT strain was 
crossed with the gsk3△ strain for the generation of haploid spores. The isogenic gsk3 
mutant strains used in this study were selected from haploid spores. The GSK3 
genotype of each mutant strain generated in this study was confirmed by PCR. To 
determine MIPS enzymatic activity, I constructed yeast strains that harbor a gene 
encoding His-Xpress tagged MIPS in their genomes. The INO1 gene in each strain was 
first knocked out with a KanMX cassette, which was replaced by an N-terminal His-
Xpress tagged INO1 cassette cloned from pRD-INO1 plasmid, which was generously 
provided by Dr. Rania Deranieh (64). The HA-MCK1 strain, which expresses a C-
terminal HA tagged Mck1, was constructed for the purpose of protein purification. The 
25 
 
 
stop codon of the MCK1 gene was replaced by a sequence that coding for the HA tag 
and a KanMX cassette.  
Growth media 
Yeast cells were grown at 30°C or 37°C in synthetic complete (SC) medium, 
which contained glucose (2% w/v), adenine (20 mg/liter), arginine (20 mg/liter), histidine 
(20 mg/liter), methionine (20 mg/liter), tryptophan (20 mg/liter), leucine (60 mg/liter), 
lysine (200 mg/liter), threonine (300 mg/liter), ammonium sulfate (0.2% w/v), inositol-
free Difco vitamin mix, vitamin-free yeast base, plus agar (2% w/v) for solid medium. 
Inositol (75 μM) and VPA (1 mM) were added separately as indicated.  
Measurement of intracellular inositol and G-6-P levels 
 Intracellular inositol levels were determined using the method of Maslanski and 
Busa with modification (174). In brief, yeast cells were lysed in dH2O containing 1X 
protease inhibitor by vortexing with acid-washed glass beads at 4°C. Cell extracts were 
mixed with 7.5% perchloric acid and centrifuged at 10,000 g for 10 min at 4°C. 
Supernatants were collected and titrated with ice cold KOH to pH 7. Samples were 
clarified by centrifugation and loaded onto columns containing 1 ml AG 1-X8 resin/H20 
(1:1) mixture. Inositol was eluted with 5 ml dH2O, eluates were dried in an oven at 70°C 
and stored at -80°C. Prior to assay, samples were dissolved in dH2O. Inositol content in 
samples was measured as described previously (62).  
To determine intracellular G-6-P levels, yeast cells were washed twice with ice-
cold dH2O and lysed in dH2O containing 1X protease inhibitor by vortexing with acid-
washed glass beads at 4°C. Cell extracts were mixed with 1 ml ice cold MeOH:CHCl3 
(2:1), vortexed, and stored at -20°C for 2 h. Samples were then mixed with extraction 
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solution (50% MeOH, 4 mM tricine pH 5.4) and centrifuged at 18,000 g for 10 min. The 
upper phase was collected and kept on ice. The lower chloroform phase was extracted 
again with extraction solution. Upper phases from both extractions were combined, 
dried with a speedvac, and stored at -80°C. Prior to assay, samples were dissolved in 
dH2O. G-6-P content in samples was measured by the enzyme-coupled fluorescence 
assay developed by Zhu et al. with modification (175).  
MIPS activity assay 
 Cells expressing His-Xpress tagged MIPS were grown to the early stationary 
phase and lysed in lysis buffer (50 mM Tris-HCl pH 7.5, 0.6 M sorbitol, 0.3 M NaCl, 1X 
protease inhibitor and 1X phosphatase inhibitor) by vortexing with acid-washed glass 
beads at 4°C. MIPS protein was purified from cell extracts using PureProteome™ Nickel 
Magnetic Bead System (Millipore). Purified MIPS protein was dialyzed (1 mM Tris 
acetate pH 8.0, 0.05 M dithiothreitol , 0.025X protease inhibitor and 0.1X phosphatase 
inhibitor) and concentrated with Amicon Ultra-0.5 Centrifugal Filter system (Millipore). 
MIPS protein concentration was determined by Bradford assay. Enzymatic activity of 3 
μg purified MIPS was determined by enzyme-coupled colorimetric assay (176). 
In vitro phosphorylation of MIPS 
 HA-Mck1 was purified from the HA-MCK1 strain by immunoprecipitation. His-
tagged MIPS was purified as described previously. 4 μg MIPS was incubated with 5 μg 
HA-Mck1 in reaction buffer (20 mM Tris-Cl pH7.5, 200 mM ATP, 1.5 μCi 32P-ATP, 10 
mM MgCl2, 5 mM DTT) for 30 min in a 1.5 ml tube. 10 μM solution from the reaction 
tube was spotted on a piece of P81 filter paper, which was washed three times in 100 
27 
 
 
ml 0.75% phosphoric acid. MIPS phosphorylation levels were determined by 
autoradiography.  
Measurement of the rate of inositol de novo synthesis in vivo 
Cells were grown in SC I+ medium to the mid log phase, washed twice with dH2O, 
transferred to SC I- medium, and incubated for 1 h or 3 h. [U-13C]glucose was added to 
a final concentration of 0.2%. After 15 min, cells were harvested and lysed in dH2O 
containing 1X protease inhibitor by vortexing with acid-washed glass beads at 4°C. 
Soluble protein in cell extract was reduced by filtration using the Amicon Ultra-0.5 
Centrifugal Filter system (Millipore). 13C labeled I-3-P and inositol in samples were 
determined by LC-MS.  
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Table 2-1. Strains used in this study.  
Strain   Genotype       Source 
W303   MATa his3, leu2, ura3, trp1, ade2    Andoh T. (173) 
mck1∆   MATα his3, leu2, ura3, trp1, ade2, mck1::TRP1   This study 
mrk1∆   MATα his3, leu2, ura3, trp1, ade2, mrk1    This study 
mds1∆   MATα his3, leu2, ura3, trp1, ade2, mds1::HIS3   This study 
ygk3∆   MATa his3, leu2, ura3, trp1, ade2, ygk3::LEU2   This study 
gsk3∆   MATa his3, leu2, ura3, trp1, ade2, mck1::TRP1, mrk1,   Andoh T. (173) 
   mds1::HIS3, ygk3::LEU2       
WY234   MATa his3, leu2, ura3, trp1, ade2, mrk1, mds1::HIS3,   This study 
   ygk3::LEU2 
His-Xpress WT  MATa his3, leu2, ura3, trp1, ade2, INO1-HIS-XPRESS  This study 
His-Xpress mck1∆ MATα his3, leu2, ura3, trp1, ade2, mck1::TRP1,   This study 
   INO1-HIS-XPRESS 
His-Xpress mrk1∆ MATα his3, leu2, ura3, trp1, ade2, mrk1, INO1-HIS-XPRESS This study 
His-Xpress mds1∆ MATα his3, leu2, ura3, trp1, ade2, mds1::HIS3,   This study 
   INO1-HIS-XPRESS 
His-Xpress ygk3∆ MATa his3, leu2, ura3, trp1, ade2, ygk3::LEU2,   This study 
   INO1-HIS-XPRESS 
His-Xpress gsk3∆ MATa his3, leu2, ura3, trp1, ade2, mck1::TRP1, mrk1,   This study 
   mds1::HIS3, ygk3::LEU2, INO1-HIS-XPRESS 
His-Xpress WY234 MATa his3, leu2, ura3, trp1, ade2, mrk1, mds1::HIS3,   This study 
   ygk3::LEU2, INO1-HIS-XPRESS 
HA-MCK1  MATa his3, leu2, ura3, trp1, ade2, MCK1-HA   This study 
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RESULTS 
mck1△ and gsk3△ cells exhibit similar features of inositol depletion  
 Our lab has previously shown that GSK3 genes are required for optimal inositol 
biosynthesis in yeast (159). To identify the yeast GSK3 gene involved in the regulation 
of inositol synthesis, I constructed single, double and triple gsk3 mutants that are 
isogenic to the gsk3∆ quadruple mutant. Consistent with our previous study, the growth 
of gsk3△ cells was greatly decreased at elevated temperatures (159). Among four gsk3 
single mutants, mck1△ was the only one that exhibited decreased growth at elevated 
temperatures (Fig. 2-1). At 37°C, mck1△ cells grew slightly slower than WT, while the 
other three single mutants grew at a rate similar to WT. The decreased growth of 
mck1△ was further exacerbated at 38°C. Interestingly, the mrk1△mds1△ygk3△ triple 
mutant, which retained MCK1 in the genome, grew slightly better than WT at 38°C. 
These findings suggest that MCK1 is required for optimal growth in I- conditions at 
elevated temperatures. Interestingly, the triple deletion of MRK1, MDS1, and YGK1 
genes benefited cell growth at elevated temperature in I- conditions.  
 VPA inhibits the growth of inositol auxotrophic strains by depleting intracellular 
inositol. We determined VPA sensitivity of gsk3 mutants. Both mck1△ and gsk3△ cells 
exhibited decreased growth in the presence of VPA, which was rescued by 
supplementation of inositol (Fig. 2-1). All other mutants grew as well as WT, suggesting 
that deletion of the MCK1 gene accounts for VPA sensitivity.  
 To determine the effects on inositol metabolism of deleting each GSK3 gene, 
intracellular inositol levels were measured in gsk3 mutants. Consistent with previous 
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Figure 2-1.  mck1△ and gsk3△ cells exhibit similar phenotypes. WT and gsk3 
mutant cells were serially diluted and spotted on SC plates supplemented with VPA (1 
mM) and inositol (75 μM) as indicated. Plates were incubated at the indicated 
temperatures for 3 days. mck1△ and gsk3△ cells exhibit decreased growth at elevated 
temperatures and in the presence of VPA. 
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studies (159), inositol levels were significantly decreased in gsk3△ cells (Fig. 2-2). The 
mck1△ strain was the only gsk3 mutant that exhibited decreased intracellular inositol 
levels compared to WT. A nearly 50% drop in intracellular inositol was observed in 
mck1△ cells, similar to the 60% decrease seen in gsk3△ cells. The other three single 
mutants exhibited levels of inositol similar to WT. Interestingly, inositol levels were 40% 
higher in the mrk1△mds1△ygk3△ triple mutant, suggesting that one or more of these 
genes inhibits inositol synthesis. In summary, deletion of MCK1 causes multiple 
features of inositol depletion, which can account for the defects observed in gsk3△ cells.  
Mck1 regulates MIPS activity 
We hypothesized that decreased intracellular inositol levels in mck1△ cells 
resulted from decreased activity of MIPS, the rate-limiting enzyme of inositol synthesis. 
To test this, I purified MIPS from cells expressing His-Xpress tagged protein. Compared 
to WT, a 50% decrease in MIPS activity was observed in mck1△ cells (Fig. 2-3). The 
other three gsk3 single mutants and the mrk1△mds1△ygk3△ triple mutant exhibited WT 
MIPS activity. I further studied the effects of VPA on MIPS activity in WT, mck1△ and 
gsk3△ cells. As shown in Fig. 2-4, VPA caused more than a 40% decrease in MIPS 
activity in WT cells. However, VPA treatment did not significantly decrease MIPS activity 
in mck1△ and gsk3△ cells. These findings suggest that MCK1 is the only GSK3 gene 
required for normal MIPS activity, and that Mck1 mediates VPA-induced MIPS inhibition. 
Inositol depletion in mck1△ cells possibly resulted from MIPS inhibition. However, Mck1 
did not phosphorylate MIPS in vitro (Fig. 2-5), suggesting that Mck1 indirectly regulates 
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Figure 2-2. Decreased intracellular inositol levels in mck1△ and gsk3△ cells. Cells 
were grown in SC medium to the early stationary phase. Intracellular inositol levels were 
determined as described in “Materials and Methods”. Values shown are mean ± SEM 
(n=9). 
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Figure 2-3. MIPS activity is decreased in mck1△ cells. Cells expressing His-Xpress 
tagged MIPS were grown in SC medium to the early stationary phase. Enzymatic 
activity of MIPS protein purified from cell extracts was determined as described in 
“Materials and Methods”. Values shown are mean ± SEM (n=6). 
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Figure 2-4. VPA does not decrease MIPS activity in mck1△ and gsk3△ cells.  
Cells expressing His-Xpress tagged MIPS were grown in SC medium to the mid log 
phase and treated with 1 mM VPA for 3 h. MIPS activities were determined as 
described in “Materials and Methods”. Values shown are mean ± SEM (n=6). 
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Figure 2-5. Mck1 does not phosphorylate MIPS in vitro. HA tagged Mck1 was 
purified from HA-MCK1 cells by immunoprecipitation. His-Xpress tagged MIPS was 
purified as described previously. Mck1 and MIPS were incubated in reaction buffer with 
32P-ATP. MIPS phosphorylation was determined by autoradiography.  
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MIPS phosphorylation, or that Mck1 requires co-factors to target MIPS in physiological 
conditions. Another possibility is that the HA tag disrupts Mck1 conformation, and 
results in catalytic inactivity. 
Surprisingly, WT and gsk3△ cells exhibited similar levels of MIPS activity. 
However, the in vitro MIPS assay does not reflect the rate of inositol synthesis in yeast 
cells in physiological conditions. Therefore, I developed an assay to determine the rate 
of inositol synthesis in vivo. 
Mck1 regulates rate of inositol de novo synthesis 
 In collaboration with Dr. Krishna Rao Maddipati, WSU Lipidomics Core director, I 
developed a novel method to measure the rate of inositol synthesis in vivo. In brief, cells 
grown in I+ medium were washed, transferred to I- medium, and grown for 1-3 h. [U-
13C]glucose was added to the media to allow synthesis of 13C labeled inositol-3-
phosphate and inositol, which were detected by LC-MS. As seen in Fig. 2-6A, mck1△ 
and gsk3△ cells exhibited significantly lower levels of [U-13C]inositol-3-phosphate 
compared to WT cells after 1 h of labeling. The differences in inositol-3-phosphate 
levels reached a maximum at 2 h. WT, mck1△ and gsk3△ cells exhibited similar levels 
of [U-13C]inositol at the 1 h time point (Fig. 2-6B). At 3 h, levels of [U-13C]inositol were 
significantly decreased in mck1△ and gsk3△ cells. However, mck1△ and WT cells 
exhibited similar levels of [U-13C]inositol. The reason for this is not clear. These results 
indicate that Mck1 is required for optimal rate of inositol synthesis in vivo. 
Mck1 possibly regulates MIPS by controlling glucose 6-phosphate availability 
 Mck1 may regulate MIPS activity by at least three mechanisms, including 
regulation of MIPS phosphorylation, MIPS protein level, and controlling the availability of 
37 
 
 
 
 
Figure 2-6. Rates of inositol-3-phosphate and inositol synthesis are decreased in 
gsk3△ and mck1△ cells. Cells were cultured in SC medium supplemented with 75 μM 
inositol to the mid log phase and transferred to SC I- media for 1-3 h. [U-13C]glucose 
was then added at a final concentration of 0.2% and cells were incubated for 15 min. 
Levels of 13C labeled I-3-P (A) and inositol (B) in cell extracts were determined by LC-
MS. Values shown are mean ± SEM (n=6). 
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glucose 6-phosphate (G-6-P), the substrate of MIPS. As described previously, Mck1 
does not phosphorylate MIPS in vitro. In addition, MIPS levels are not decreased in 
mck1△ and gsk3△ cells (data not shown). To address the third possibility, we measured 
intracellular G-6-P levels in mck1△ and gsk3△ cells. Compared to WT, the intracellular 
G-6-P levels were 80% and 70% lower in gsk3△ and mck1△ cells, respectively (Fig. 2-
7). In addition, intracellular G-6-P levels were 75% lower in WT cells treated with VPA 
(shown and discussed in Chapter 4). These results suggest that Mck1 regulates MIPS 
by controlling G-6-P levels, and that VPA-induced inositol depletion is possibly a 
combined outcome of both G-6-P depletion and MIPS inhibition.  
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Figure 2-7. Intracellular G-6-P levels are decreased in mck1△ and gsk3△ cells. 
Cells were grown in SC medium to the early stationary phase. Intracellular G-6-P levels 
were determined as described in “Materials and Methods”. Values shown are mean ± 
SEM (n≥8). 
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DISCUSSION 
 The current study discovered for the first time that the yeast GSK3 gene MCK1 
regulates inositol synthesis. Major findings of this study are as follows. 1) Mck1 is 
required for optimal intracellular inositol levels and MIPS activity. 2) VPA inhibits MIPS 
enzymatic activity via Mck1. 3) The rate of inositol synthesis is decreased in mck1△ and 
gsk3△ cells in vivo. 4) mck1△ and gsk3△ cells exhibit decreased intracellular G-6-P 
levels. These findings identify Mck1 as a regulator of inositol de novo synthesis in yeast.   
 Among the four single mutant strains mck1△, mrk1△, mds1△, and ygk3△, only 
mck1△ cells exhibited decreased growth at elevated temperatures, as observed in 
gsk3△ cells (Fig. 2-1), while mrk1△, mds1△ and ygk3△ cells grew as WT.  In addition, 
mck1△ and gsk3△ exhibit severely decreased growth in the presence of VPA. The other 
three gsk3 single mutants grew normally compared to WT. The addition of inositol to 
growth media rescued sensitivities to VPA in mck1△ and gsk3△ cells. VPA has been 
shown to deplete intracellular inositol and inhibits the growth of inositol auxotrophs 
(60,64,159). These findings suggest that mck1△ cells are defective in inositol synthesis. 
Therefore, exogenous inositol must be provided to maintain normal levels of inositol in 
these cells. In fact, the intracellular inositol levels in mck1△ cells decreased to levels 
similar to those of gsk3△ cells (Fig. 2-2). The other three single mutants, mrk1△, mds1△ 
and ygk3△, exhibited normal inositol levels. In addition, the simultaneous deletion of 
MRK1, MDS1 and YGK3 did not result in any features of inositol depletion, suggesting 
that only MCK1 was required for optimal inositol levels.   
 MIPS purified from mck1△ cells exhibited decreased enzymatic activity (Fig. 2-3), 
suggesting that MCK1 is required for optimal MIPS activity. MIPS is a phosphoprotein, 
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and the phosphorylation of MIPS has been reported to regulate its enzymatic activity 
(63,64). Yeast MIPS contains a potential GSK3 phosphorylation site, Ser-296. 
Phosphorylation of this site up-regulates MIPS activity (64), which is consistent with our 
finding that Mck1 positively regulates MIPS activity.  On the other hand, phosphorylation 
of MIPS Ser-184, which is a potential PKA phosphorylation site, downregulates MIPS 
activity (64). Interestingly, Mck1 has been reported to inhibit PKA activity in yeast (177). 
Therefore, MCK1 ablation may contribute to increased phosphorylation on Ser-184. 
These findings suggest that MIPS inhibition in mck1△ cells results from decreased 
activating phosphorylation of Ser-296 and increased inhibitory phosphorylation of Ser-
184. However, Mck1 did not phosphorylate MIPS in vitro (Fig. 2-5), suggesting that 
Mck1 may need co-factors to phosphorylate MIPS in vivo, or that the effect of Mck1 is 
indirect, e.g., via a kinase activated by Mck1. It is also possible that the HA tag inhibits 
Mck1 catalytic activity. VPA has been shown to inhibit mammalian GSK3 in several 
studies (117-120). As a yeast GSK3 homolog, Mck1 is a possible target of VPA. In 
support of this hypothesis, VPA did not inhibit MIPS activity in mck1△ and gsk3△ cells 
(Fig. 2-4). PKA, AKT, and PKC signaling pathways are also affected by VPA treatment 
(65-67). Further studies are required to determine if these pathways mediate VPA-
induced MIPS inhibition. Taken together, these studies indicate that Mck1 mediates 
VPA-induced MIPS inhibition by regulating MIPS phosphorylation. 
 We determined rates of inositol synthesis under physiological conditions in WT, 
mck1△ and gsk3△ cells. As shown in Fig. 2-6, rates of synthesis of inositol-3-phosphate 
and inositol were decreased in mck1△ cells, which is consistent with decreased MIPS 
activity and decreased inositol levels observed in mck1△ cells. Therefore, the 
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decreased rate of inositol synthesis in mck1△ cells is caused, at least in part, by 
decreased MIPS activity. Surprisingly, rates of I-3-P and inositol synthesis in vivo, but 
not MIPS activity determined in vitro, were decreased in gsk3△ cells, which suggested 
the involvement of a second level of regulation of inositol synthesis. Previous studies 
have shown that the glycolytic intermediate dihydroxyacetone phosphate (DHAP) is a 
strong inhibitor of MIPS (178,179). The accumulation of intracellular DHAP leads to 
inositol auxotrophy (178), suggesting a link between perturbation of glycolysis and 
inhibition of inositol de novo synthesis. Furthermore, Mck1 negatively regulates the 
activity of  pyruvate kinase (177,180), which catalyzes the final and irreversible step of 
glycolysis in yeast (181). The levels of pyruvate kinase influence the glycolytic flux in 
yeast cells (182), which suggests that increased pyruvate kinase activity in mck1△ cells 
may increase the flux of G-6-P into glycolysis. In fact, the intracellular G-6-P levels were 
significantly decreased in mck1△ and gsk3△ cells (Fig. 2-7). The limited availability of 
G-6-P may contribute to the decreased rates of inositol synthesis in mck1△ and gsk3△ 
cells. It is possible that the regulation of inositol de novo synthesis is regulated at the 
level of G-6-P flux.  
 This study demonstrates for the first time that the yeast GSK3 homolog MCK1 is 
required for optimal rate of inositol synthesis. mck1△ cells exhibit multiple features of 
inositol depletion and decreased intracellular G-6-P levels. In addition, Mck1 mediates 
VPA-induced MIPS inhibition. Future studies should focus on the elucidation of potential 
mechanisms by which Mck1 regulates MIPS activity. 
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CHAPTER 3  INOSITOL HEXAKISPHOSPHATE KINASE 1 (IP6K1) REGULATES 
INOSITOL SYNTHESIS IN MAMMALIAN CELLSINTRODUCTION  
 
The work described in this chapter has been published in Yu, W., Ye, C., and 
Greenberg, M. L. (2016) Inositol Hexakisphosphate Kinase 1 (IP6K1) Regulates Inositol 
Synthesis in Mammalian Cells. The Journal of biological chemistry 291, 10437-10444 
(183) .   
INTRODUCTION 
Inositol is a ubiquitous six-carbon cyclitol that is essential for viability of 
eukaryotic cells.  Myo-inositol, physiologically the most important stereoisomer of 
inositol, is the precursor of all inositol compounds, including phosphoinositides, inositol 
phosphates, inositol sphingolipids, and glycosylphosphatidylinositols. Inositol 
compounds are essential for gene expression (167), trafficking (27), signal transduction 
(20) and membrane biogenesis (168). The crucial role of inositol is underscored by the 
link between perturbation of inositol metabolism and human disorders (18). Therefore, 
elucidating the mechanisms underlying the control of inositol homeostasis is expected 
to have important implications for understanding cell function and the pathologies 
underlying many illnesses. 
While cellular inositol can be obtained from the extracellular environment or by 
recycling inositol lipids (7,23), the de novo synthesis of inositol is essential for inositol 
homeostasis and cellular proliferation when environmental inositol is limiting (160,184). 
Inositol synthesis is a two-step reaction in which glucose-6-phosphate (G6P), the 
branch point metabolite for glycolysis, the pentose phosphate pathway, and inositol 
synthesis, is converted to inositol-3-phosphate, which is dephosphorylated to inositol. 
The first and rate-limiting step of inositol synthesis is catalyzed by inositol-3-phosphate 
synthase (8-10,169,170). Significantly high levels of inositol are found in brain tissue, 
which has limited access to exogenous inositol (14), suggesting that de novo synthesis 
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of inositol is critical for normal brain function. Importantly, alterations in inositol 
metabolism have been associated with bipolar disorder and Alzheimer’s disease 
(18,37,185). 
Despite its importance, little is known about the regulation of inositol synthesis in 
mammals. In contrast, the regulation of inositol synthesis has been well-characterized in 
the budding yeast Saccharomyces cerevisiae. Inositol synthesis in yeast is regulated at 
the level of transcription of INO1 (171,172), the gene that codes for inositol-3-phosphate 
synthase, and by phosphorylation of the Ino1 protein (64). INO1 expression is controlled 
by the transcriptional repressor Opi1 in response to inositol and phosphatidic acid (PA) 
levels (56). Opi1 is stabilized by physically interacting with PA on the endoplasmic 
reticulum (ER) membrane. When inositol is limiting, PA levels are increased, Opi1 
remains in the ER, and INO1 transcription is derepressed to increase inositol synthesis. 
When inositol levels are abundant, PA is rapidly consumed for phosphatidylinositol 
synthesis, Opi1 is released from the ER and translocates into the nucleus, where it 
represses INO1 transcription resulting in decreased inositol synthesis. We have recently 
demonstrated that transcription of INO1 in yeast is regulated by the synthesis of inositol 
pyrophosphates, as INO1 transcription requires the Kcs1-catalyzed synthesis of 
diphosphoinositol tetrakisphosphate (PP-IP4) (167).  
In contrast to inositol synthesis in yeast, transcription of Isyna1 (the mammalian 
homolog of yeast INO1, which we refer as mINO1 in this report), is not regulated in 
response to inositol (160,186). However, in the current study, we demonstrate for the 
first time that inositol synthesis in mouse embryonic fibroblast (MEF) cells is regulated 
by inositol pyrophosphate. Knockout of inositol hexakisphosphate kinase IP6K1 [which 
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catalyzes the formation of pyrophosphate at position five of inositol pentakisphosphate 
/inositol hexakisphosphate to generate 5PP-IP4/5PP-IP5 (IP7), respectively (187)], led to 
increased transcription and altered DNA methylation of mINO1. This resulted in 
increased levels of mIno1 protein and increased intracellular inositol. Thus, in contrast 
to positive regulation of INO1 in yeast, inositol pyrophosphate negatively regulates 
mINO1 transcription. Intriguingly, similar to the yeast transcriptional repressor Opi1, 
IP6K1 protein bound with high affinity to PA. Deletion of the PA-binding sequence 
abrogated both nuclear localization of IP6K1 and repression of mINO1 transcription. 
Our findings suggest a model whereby inositol pyrophosphate negatively regulates 
inositol synthesis by PA-facilitated entry into the nucleus and repression of mINO1 
transcription. 
MATERIALS AND METHODS 
Cell lines, yeast strains, and growth conditions 
Wild type, IP6K1-KO, IP6K1-KO +pMX-IP6K1 and IP6K1-KO +pMX-EV MEF cell 
lines (kindly provided by Dr. Anutosh Chakraborty, Scripps Research Institute), were 
grown in DMEM (Gibco) containing 10% FBS (Hyclone) and penicillin (100 units/m)/ 
streptomycin (100 μg/ml) (Invitrogen) (188). IP6K1-KO +pMX-IP6K1 and IP6K1-KO 
+pMX-EV cells were grown in this media supplemented with 4μg/ml blasticidin (Sigma). 
The yeast S. cerevisiae kcs1∆ strain was obtained from Yeast Deletion Clones 
(Invitrogen). Yeast cells were grown at 30°C or 37°C in synthetic complete (SC) medium, 
which contained glucose (2% w/v) and necessary supplements including adenine (20 
mg/liter), arginine (20 mg/liter), histidine (20 mg/liter), methionine (20 mg/liter), 
tryptophan (20 mg/liter), leucine (60 mg/liter), lysine (200 mg/liter), threonine (300 
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mg/liter), ammonium sulfate (0.2% w/v), inositol-free Difco vitamin mix, vitamin-free 
yeast base, plus agar (2% w/v) for solid medium. Inositol (75 μM) was added separately 
as indicated.  
Real-time PCR 
MEF cells were grown in DMEM containing 10% FBS. RNA was extracted from 
cells by using RNeasy plus Mini Kit (QIAGEN), and was converted to cDNA with a 
Transcriptor First Strand cDNA Synthesis Kit (Roche). RT-PCR was performed using 
Brilliant III Ultra-Fast SYBR green qPCR master mix (Agilent) and MX3000p qPCR 
System (Agilent). mRNA levels were normalized to GAPDH. 
Immunoblotting 
Cells were harvested, washed with ice-cold PBS and lysed by vortexing in lysis buffer 
(50 mM Tris-HCL, 125 mM NaCl, 1% NP40, 2 mM EDTA and 1X protease inhibitor) for 
30 min at 4°C. Protein concentration was determined using a Pierce BCA Protein Assay 
Kit (Thermo). Cell extract corresponding to 30 μg protein was analyzed by SDS-PAGE 
on a 10% gel. Immunoblotting was performed using primary antibodies against mIno1 
(ISYNA1) (sc-134687, rabbit, Santa Cruz), IP6K1 (GTX103949, rabbit, Gene Tex), β-
actin (sc-69879, mouse, Santa Cruz) and corresponding secondary antibodies.  
Measurement of intracellular inositol and G-6-P levels in MEF cells 
Intracellular inositol levels were determined as described before using the 
method of Maslanski and Busa (174). In brief, MEF cells were lysed in lysis buffer (50 
mM Tris-HCL, 125mM NaCl2, 1% NP40 and 2mM EDTA) at 4°C. Cell extracts were 
mixed with 7.5% perchloric acid and centrifuged at 10,000 g for 10 min at 4°C. 
Supernatants were collected and titrated with ice cold KOH to pH 7. Samples were 
47 
 
 
clarified by centrifugation and loaded onto columns containing 1 ml AG 1-X8 resin/H20 
(1:1) mixture. Inositol was eluted with 5 ml dH2O, eluates were dried in an oven at 70°C 
and stored at -80°C. Prior to assay, samples were dissolved in dH2O. Inositol content in 
samples was measured as described previously (62).  
To determine intracellular G-6-P levels, MEF cells were washed twice with ice 
cold PBS. Cell pellets were mixed with 1 ml ice cold MeOH:CHCL3 (2:1), vortexed and 
stored at -20°C for 2 h. Samples were then mixed with extraction solution (50% MeOH, 
4 mM tricine pH 5.4) and centrifuged at 18,000 g for 10 min. The upper phase was 
collected and kept on ice. The lower chloroform phase was extracted again with 
extraction solution. Upper phases from both extractions were combined, dried with a 
speedvac, and stored at -80°C. Prior to assay, samples were dissolved in dH2O. G-6-P 
content in samples was measured by the enzyme-coupled fluorescence assay 
developed by Zhu et al. with modification (175).  
Protein lipid overlay assay 
pGEX-6P-2 plasmids harboring IP6K1 variants were constructed using a Q5 Site-
Directed Mutagenesis Kit (NEB) with pGEX-6P-2-IP6K1 (from Dr. Anutosh Chakraborty) 
as template. pGEX-6P-2-IP6K1 and corresponding mutants were transformed into BL21 
(DE3) pLysS cells for IPTG-induced overexpression. E. coli cells were lysed by French 
press to obtain cell extracts. IP6K1 proteins were then purified from E.coli cell extracts 
using a GST spin purification kit (Life Technology). A protein lipid overlay assay was 
performed according to the protocol of Dowler and co-workers with modification (189). 
In brief, lyophilized lipids were dissolved in a 1:1 solution of methanol and chloroform to 
make 1 mM stocks. Lipids were diluted to concentrations ranging from 500 to 5 μM in a 
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2:1:0.8 solution of methanol:chloroform:water. Then 1 μl lipid samples from each dilution 
were spotted on nitrocellulose membranes. After drying for 1 h at room temperature, 
membranes were incubated in blocking buffer (50 mM Tris-HCL pH 7.5, 150 mM NaCl2, 
0.1% Tween 20 and 2 mg/ml BSA) with gentle rocking for 1 h at room temperature. 
Membranes were incubated overnight at 4°C with gentle rocking in 10 ml blocking buffer 
containing 25 μg purified IP6K1 proteins. IP6K1 proteins bound to lipid drops on the 
membrane were detected by immunoblotting using primary antibodies against IP6K1 
(GTX103949, rabbit, Gene Tex) and corresponding secondary antibodies. 
Fluorescence microscopy 
pEGFP-C1 plasmids harboring IP6K1 variants were constructed using a Q5 Site-
Directed Mutagenesis Kit (NEB) with pEGFP-C1-IP6K1 (from Dr. Anutosh Chakraborty) 
as template. IP6K1-KO cells were transfected with pEGFP-C1-IP6K1 plasmid and 
corresponding mutants using Lipofectamine 2000 (Life technology). Fluorescence 
microscopy was performed using an Olympus BX41 fluorescence microscope. Images 
were acquired using an Olympus Q-Color3 camera operated by QCapture2 software. All 
pictures were taken at 400X at room temperature. 
Determination of DNA methylation levels 
Genomic DNA samples extracted from WT and IP6K1-KO cells using a Wizard 
Genomic DNA Purification Kit (Promega) were subjected to DNA bisulfite conversion 
using an EZ DNA Methylation-Gold Kit (Zymo Research), and sequencing for the 
determination of methylation levels. 
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Table 3-1. RT-PCR primers used in this study  
    ________________________________________________________ 
  Gene    Sequence 
  mINO1 (Isyna1)  CCTGTAGTGAATGCCCTCTTC  
       CGCTCCATCTTGTGCTCTAATA  
 
  Gapdh1   AACAGCAACTCCCACTCTTC  
      CCTGTTGCTGTAGCCGTATT  
    ________________________________________________________ 
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RESULTS 
IP6K1 rescues inositol deficiency in the yeast kcs1Δ mutant 
We have previously shown that Kcs1-catalyzed inositol pyrophosphate synthesis 
is required for optimal transcription of INO1 in yeast (167). To determine if mouse IP6K1 
can supply the function of yeast Kcs1, we expressed IP6K1 in the yeast kcs1∆ mutant. 
As seen in Fig. 3-1, kcs1∆ mutant cells expressing the wild type IP6K1 gene grew 
normally, while the kinase-dead IP6K1 (IP6K1KD) gene (28) failed to support growth of 
the kcs1∆ mutant. Therefore, mouse IP6K1 is the functional homolog of yeast Kcs1, 
which can rescue defective inositol synthesis in yeast by restoring inositol 
pyrophosphate synthesis. 
IP6K1 is a negative regulator of inositol synthesis in MEF cells 
To ascertain if IP6K1 regulates mammalian inositol synthesis, we determined the 
effects of knocking out IP6K1 (IP6K1-KO). Surprisingly, IP6K1-KO cells exhibited a 5-
fold increase in mINO1 mRNA levels (Fig. 3-2A). Consistent with increased transcription, 
mIno1 protein levels were also increased in IP6K1-KO cells (Fig. 3-2B), and inositol 
levels were 75% higher in the IP6K1-KO cells than in WT cells (Fig. 3-2C). Levels of 
intracellular G-6-P, the substrate for inositol synthesis, decreased correspondingly (Fig. 
3-2D). Taken together, these findings indicate that IP6K1 is a negative regulator of 
inositol synthesis.  
IP6K1 regulates mINO1 DNA methylation 
 As seen in Fig. 3-2B, two mIno1 proteins were expressed in IP6K1-KO cells. A 
previous study reported that alternative splicing of mINO1 results in α, β, and γ mRNA 
transcripts, which generate protein isoforms (190). The α transcript is the full-length 
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Figure 3-1. IP6K1 rescues kcs1∆ inositol auxotrophy. Serial dilutions of yeast kcs1∆ 
cells transformed with indicated plasmids were spotted on synthetic complete Ura- 
medium in the presence or absence of 75 μM inositol. Plates were incubated at the 
indicated temperatures for 3 days.  
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Figure 3-2. Inositol synthesis is up-regulated in IP6K1-KO cells. A, mINO1 mRNA 
levels are increased in IP6K1-KO cells. mINO1 mRNA levels were determined by RT-
PCR (n=4) (*p<0.05). B, mIno1 protein levels were profoundly increased in IP6K1-KO 
cells (left). The expression of IP6K1 in IP6K1-KO cells restored mIno1α and mIno1γ 
levels (right). 30 μg total cell extract from each sample were subjected to Western blot 
analysis using 10% SDS-PAGE gel. C, IP6K1-KO cells exhibited increased intracellular 
inositol levels. Intracellular inositol levels in MEF cells were determined as described in 
“Experimental procedures” (n=6) (*p<0.05). D, Intracellular G6P levels were decreased 
in IP6K1-KO cells. Intracellular G6P levels in MEF cells were determined by enzyme-
coupled fluorescence assay as described in “Experimental procedures” (n=6) (*p<0.05). 
Values are mean ± SEM. Statistical significance was determined by unpaired t test. 
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mRNA, the β mRNA contains a truncated exon 2, and the γ mRNA is transcribed from a 
second ATG site within the unremoved intron 4. To determine which isoforms are 
expressed in IP6K1-KO cells, we compared cDNA from WT and IP6K1-KO cells by 
PCR analysis, using specific primers that distinguished among these mRNAs. Both the 
α and γ mRNAs were present in the IP6K1-KO cells, but only the α mRNA was detected 
in WT cells (data not shown). These findings indicated that isoforms observed in Fig. 3-
2B are translated from the α (upper band) and γ (lower band) splicing forms.   
Previous studies indicated that in vitro methylation of the human INO1 promoter 
significantly decreased reporter gene expression (191). To determine if altered DNA 
methylation could account for the mIno1 isoforms observed in IP6KO cells, we analyzed 
methylation of mINO1 DNA using DNA bisulfite conversion of WT and IP6K1-KO 
genomic DNA followed by probing with primers targeting the sequence from – 286 to 
+160, which is enriched in CpG islands (Fig. 3-3).  In the mINO1 promoter region, most 
of the CpG sites exhibited a similar, but slightly decreased, pattern of methylation in 
IP6K1-KO cells compared to WT cells. However, the CpG sites between the first and 
second ATGs exhibited markedly less methylation in IP6K1-KO cells. These findings 
suggest that IP6K1 may negatively regulate mINO1 transcription by increasing the 
methylation of mINO1 DNA.  
IP6K1 requires PA-binding for nuclear localization and repression of mINO1 
transcription  
 As discussed above, negative regulation of INO1 transcription in yeast is 
mediated by the Opi1 transcriptional repressor. While homologs of Opi1 have not been 
identified in mammalian cells, we considered the possibility that IP6K1 may exhibit 
functional similarity to Opi1. Opi1 is retained in the cytoplasm by binding to PA, and 
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Figure 3-3. Methylation pattern of mINO1 DNA is altered in IP6K1-KO cells. A, DNA 
methylation levels in MEF cells were determined as described in “Experimental 
procedures”. CpG islands are depicted as balloons. Methylated cytosines are filled, and 
unmethylated cytosines are unfilled. B, Raw data of mINO1 DNA methylation 
experiment. CpG islands are depicted in bold. Methylated cytosines are depicted in red, 
whereas unmethylated cytosines are depicted in black. CpG islands with altered 
methylation in IP6K1-KO cells are highlighted with yellow shade, and the start codon is 
highlighted with green shade. 
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translocates to the nucleus when PA is limiting. As shown in the protein lipid overlay 
assay (Fig. 3-4A), purified recombinant IP6K1 displayed a markedly high affinity to PA, 
and only weak binding to other phospholipids. 
To determine the functional significance of PA-binding, we constructed the IP6K1 
deletions shown in Fig. 3-5 and determined the ability of truncated proteins to bind PA. 
Deletion of Q2 but not the other sequences greatly diminished PA-binding activity of 
IP6K1 (Fig. 3-4B). The Q2 domain alone was sufficient for PA-binding (Fig. 3-4D). We 
then determined the effect of Q2 deletion on localization of IP6K1. IP6K1-KO cells 
expressing GFP-tagged wild type IP6K1 exhibited intense fluorescence in the nucleus in 
about 75% of cells (Fig. 3-6). Deletion of the Q2 domain resulted in decreased nuclear 
localization in more than 60% of cells. Interestingly, IP6K1-KO cells expressing GFP-
Q2∆ exhibited increased mINO1 mRNA levels compared to cells expressing wild type 
IP6K1 (Fig. 3-7). These results indicate that interaction with PA facilitates IP6K1 nuclear 
localization and is required by IP6K1 to repress mINO1 expression.  
Protein BLAST sequence alignment identified a small region of sequence 
homology between the Q3 domain of IP6K1 and yeast Opi1, especially in the region of 
positively charged residues that are critical to the PA-binding activity of the yeast protein 
(Fig. 3-5). The IP6K1 region containing these sequences was designated HOPA 
(Homology to Opi1 PA-binding). To determine the function of the HOPA domain, we 
constructed an IP6K1 mutant in which this region is deleted (HOPA∆). The HOPA∆ 
protein exhibited normal PA-binding activity (Fig. 3-4C) as expected, as PA-binding is 
conferred by the Q2 domain. Strikingly, however, deletion of the HOPA domain resulted 
in exclusion of IP6K1 from the nucleus in more than 70% of cells (Fig. 3-6).  Consistent 
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Figure 3-4. IP6K1 binds preferentially to phosphatidic acid (PA). A, IP6K1 protein 
was purified from E. coli cells expressing the IP6K1 gene on the pGEX-6-P2 
overexpression vector. Serial dilutions of the indicated lipids were spotted on a 
nitrocellulose membrane, which was incubated overnight in buffer containing 25 μg of 
IP6K1 protein. Interactions between IP6K1 and lipids were determined by 
immunoblotting. B, Deletion of the Q2 domain of IP6K1 decreased binding to PA. C, 
Deletion of the HOPA domain of IP6K1 did not affect binding to PA. D, Q2 domain of 
IP6K1 binds to PA.  
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Figure 3-5. IP6K1 exhibits sequence homology to yeast Opi1 (upper panel).  The 
IP6K1 HOPA domain that exhibits homology to the PA-binding domain of yeast Opi1 is 
highlighted in red. The catalytic motif of IP6K1 is highlighted in blue. The PA-binding 
domain of yeast Opi1 is highlighted in gray. The nuclear localization signal (NLS) of 
yeast Opi1 is underlined in purple. IP6K1 deletion mutants were constructed by site-
directed mutagenesis according to the schematic figure (lower panel). Residues deleted 
are indicated by numbers above the bar. 
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Figure 3-6. PA-binding is required for nuclear localization of IP6K1. IP6K1-KO cells 
were transfected with plasmids harboring GFP-tagged WT or mutant IP6K1. Intracellular 
localization of IP6K1 (upper panel) was determined by fluorescence microscopy. The 
number of cells showing each phenotype (lower panel) was determined in three 
independent experiments (n > 150). Values are mean ± SEM.  
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Figure 3-7. PA-binding to IP6K1 is required for repression of mINO1 transcription. 
IP6K1-KO cells were transfected with plasmids harboring the indicated GFP-tagged 
IP6K1 mutants. The mINO1 mRNA levels were determined by RT-PCR (2 independent 
experiments with 2 replicates) (*p<0.05). Values are mean ± SEM. Statistical 
significance comparing transcription levels to KO+IP6K1 control was determined by 
unpaired t test.  
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with this finding, cNLS Mapper predicts a potential nuclear localization signal (NLS) in 
the HOPA domain. Interestingly, the NLS of yeast Opi1 is in the homologous region (Fig. 
3-5). Expression of HOPA∆ in IP6K1-KO cells resulted in increased mINO1 mRNA 
levels relative to cells expressing WT IP6K1 (Fig. 3-7). The catalytic motif of IP6K1 also 
lies in the Q3 domain (192,193). Expression of Q3∆, which lacks both the HOPA 
domain and the catalytic motif, also led to increased mINO1 mRNA levels in IP6K1-KO 
cells (Fig. 3-7).  
The Q1∆ deletion did not affect nuclear localization (Fig. 3-6) or mINO1 mRNA 
levels. Although the Q4∆ deletion did not affect nuclear localization (Fig. 3-6), it resulted 
in increased mINO1 transcription (Fig. 3-7). The Q4 domain contains the ATP-binding 
motif (192,193), which is critical for IP6K1 catalytic activity (28,194,195). Increased 
mINO1 transcription in IP6K1-KO cells expressing Q4∆ indicates that IP6K1 requires 
catalytic activity to suppress mINO1 expression. Together, these findings indicate that 
binding of PA is required for localization of IP6K1 to the nucleus, where the ATP-binding 
dependent synthesis of inositol pyrophosphate represses mINO1 transcription.  
DISCUSSION  
Despite the essential role of inositol in cell function, the mechanisms that 
regulate inositol synthesis in mammalian cells have not been characterized. The current 
study demonstrates for the first time that de novo synthesis of inositol in MEF cells is 
regulated by inositol hexakisphosphate kinase 1 (IP6K1), which mediates transcriptional 
control of the gene (mINO1) coding for the rate-limiting enzyme of inositol synthesis. 
Our findings indicate that IP6K1 alters methylation and negatively regulates 
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transcription of mINO1, and that binding of IP6K1 to PA is essential for nuclear 
localization of IP6K1 and repression of transcription.  
IP6K1-KO cells exhibited increased expression of mINO1 (Fig. 3-2A), which was 
accompanied by increased mIno1 protein and inositol levels (Fig. 3-2B,C). These 
findings indicate that IP6K1 is a negative regulator of mINO1 transcription. Increased 
mINO1 expression in IP6K1-KO cells is most likely due to decreased DNA methylation 
(Fig. 3-3), which is associated with silencing of gene expression (196). Seelan et al. 
investigated the effects of methylation of the INO1 promoter on transcription of INO1 in 
human neuroblastoma cells transfected with plasmids carrying in vitro methylated INO1 
(191). They determined that the methylated INO1 promoter led to significantly less 
transcription than the non-methylated control. Our finding that IP6K1-KO cells exhibited 
both increased mINO1 transcription and decreased DNA methylation is the first in vivo 
demonstration of regulation of mINO1 by in vivo methylation.  
Two lines of evidence support a role for regulation of methylation by inositol 
pyrophosphate. First, IP7 (the product of IP6K1) was shown to inhibit Akt (197), which 
negatively regulates methylation of imprinted genes (198). Therefore, the deficiency of 
IP7 in IP6K1-KO cells may lead to decreased mINO1 methylation as a result of 
increased Akt signaling. Second, IP6K1 associates with chromatin and controls histone 
demethylation by regulating the demethylase Jumonji domain-containing 2C (JMJD2C), 
which catalyzes the removal of trimethyl groups from lysines 9 and 36 of histone H3 
(26). IP6K1-KO cells exhibited decreased levels of histone H3 lysine 9 trimethylation 
(H3K9me3) and increased transcription of JMJD2C-regulated genes. Interestingly, DNA 
regions associated with H3K9me3 exhibited increased methylation (199), while mutation 
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of H3K3 led to decreased DNA methylation (200). In this light, IP6K1 may regulate 
mINO1 methylation indirectly by regulating histone modification.  
IP6K1 exhibits dual localization in the cytoplasm and nucleus (Fig. 3-6). The 
probable NLS of IP6K1 was localized to the Q3 domain, the deletion of which led to 
exclusion of IP6K1 from the nucleus (Fig. 3-6).  Binding of the IP6K1 Q2 domain to PA 
is essential for translocation of the protein to the nucleus and repression of mINO1 
transcription (Figs. 3-6, 3-7). Binding to PA has been shown to promote nuclear 
localization of transcription factor WER in Arabidopsis (201,202). Inhibition of 
phospholipase D (PLD), resulting in decreased conversion of phosphatidylcholine 
(PC) to PA, suppresses nuclear localization of WER (202). Nuclear association of PLD 
has been reported both in mammals and plants (203,204). Furthermore, PA synthesis 
has been demonstrated in the nuclear envelope of mammalian cells (205,206), and PA 
has been detected in the nucleus (207). To our knowledge, the current study is the first 
to report the dependence on binding to PA for nuclear localization of a mammalian 
protein.   
The catalytic function of IP6K1 is necessary for repression of mINO1 
transcription, as deletion of the Q4 domain resulted in increased mINO1 expression (Fig. 
3-7). The “SLL” ATP-binding motif, which is highly conserved in the inositol 
polyphosphate kinase (IPK) family, is localized in the Q4 domain (192,193), and 
mutation of the ATP-binding site impairs catalysis (28,194). Therefore, the synthesis of 
inositol pyrophosphate is required for repression of mINO1 transcription. 
Surprisingly, while Kcs1 and IP6K1 carry out the same enzymatic function, they 
regulate INO1 expression in an opposite manner in yeast and mouse cells. INO1 
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expression is positively regulated in yeast by Kcs1 (167) but negatively regulated by 
IP6K1 in mouse cells (Fig. 3-2A).  In fact, the observed negative regulation of mINO1 
expression by IP6K1 more closely resembles that of the yeast transcriptional repressor 
Opi1. Both Opi1 and IP6K1 bind to PA, translocate from the cytoplasm to the nucleus, 
and repress INO1 transcription. However, while PA-binding retains Opi1 in the 
cytoplasm, PA-binding mediates IP6K1 nuclear translocation (Fig. 3-6). In yeast, PA 
levels indirectly reflect inositol synthesis, which regulates INO1 expression.  As inositol 
does not regulate INO1 expression in mammalian cells (9, 22), we speculate that PA 
levels may reflect the state of cellular energy metabolism, which would affect inositol 
synthesis as a result of competition for the common substrate G-6-P. 
Inositol pyrophosphate regulation is an intriguing area of signaling research. 
Shears suggested that inositol pyrophosphates are metabolic messengers that respond 
to the cellular energy demand (208). In support of this concept, perturbing the energy 
balance in mammalian cells leads to decreased synthesis of inositol pyrophosphates 
(209). Interestingly, inositol pyrophosphate deficiency in yeast kcs1∆ cells leads to 
dysfunctional mitochondria with greatly reduced respiratory capacity (210). To 
compensate, glycolysis is increased to generate ATP. G-6-P is the branch point of 
inositol de novo synthesis and glycolysis. We observed decreased intracellular G-6-P 
levels in IP6K1-KO cells (Fig. 3-2D), which may be caused, at least in part, by increased 
inositol synthesis. Therefore, IP6K1 may repress mINO1 expression to maintain inositol 
synthesis at a relatively low level, reserving G-6-P for glycolysis.  
Our findings suggest the following model (Fig. 3-8). Translocation of IP6K1 to the 
nucleus is facilitated by interaction with PA. In the nucleus, IP6K1 associates with 
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chromatin and synthesizes IP7/PP-IP4. IP7/PP-IP4 inhibits transcription of mINO1 by 
increasing methylation of mINO1 DNA, inhibiting the recruitment of transcription factors 
to the promoter region of mINO1, or perturbing assembly of the transcription complex. 
This study is the first to describe the molecular control of de novo synthesis of inositol in 
mammalian cells, and suggests that inositol synthesis and cellular energy demand are 
coordinately controlled. These findings have important implications for understanding 
essential cellular functions that are dependent on inositol, and human disorders that 
result from perturbation of inositol homeostasis. 
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Figure 3-8. Model of regulation of mINO1 transcription by IP6K1. PA-binding 
facilitates localization of IP6K1 to the nucleus, where it associates with chromatin and 
synthesizes IP7/PP-IP4. IP7/PP-IP4 represses mINO1 expression by promoting 
methylation of mINO1 DNA and/or inhibiting the transcription apparatus.  
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CHAPTER 4  VPA INHIBITS EXPRESSION OF HEXOSE TRANSPORTER GENES 
HXT2 AND HXT4 VIA TRANSCRIPTION REPRESSOR MIG1  
INTRODUCTION 
 VPA has been used for decades for the treatment of bipolar disorder. However, 
the therapeutic mechanism underlying this drug is not well understood, which hinders 
the development of novel anti-bipolar drugs with improved efficacy. Among many 
biochemical outcomes of VPA treatment, VPA-induced inositol depletion has been 
proposed as one potential mechanism (31). In Saccharomyces cerevisiae cells, VPA 
depletes intracellular inositol by inhibiting myo-inositol-3-phosphate synthase (MIPS) 
(59,60,64), which catalyzes the rate-limiting step of inositol de novo synthesis (8-
10,169,170). In addition, VPA was shown to upregulate expression of glycolysis genes 
in yeast (unpublished data of Shyamala Jadhav). Interestingly, MIPS activity is greatly 
inhibited by the glycolysis intermediate dihydroxyacetone phosphate (DHAP) (178,179). 
Yeast mutants that accumulate intracellular  DHAP are inositol auxotrophs (178). These 
findings suggest that inositol de novo synthesis and glycolysis are intrinsically 
coordinated. As both glycolysis and inositol synthesis pathways utilize glucose 6-
phosphate (G-6-P) as the common substrate, VPA-induced perturbation of glycolysis 
and inositol synthesis may both result from changes in G-6-P metabolism. 
 Glucose is the preferred carbon source for most eukaryotic cells. To adapt to 
fluctuation of glucose in the environment, yeast cells developed mechanisms to sense 
and respond to glucose availability. The first step in the regulation of glucose 
metabolism is glucose uptake, which is regulated by the transcription of hexose 
transporter (HXT) genes (211). Twenty genes that encode proteins in the hexose 
transporter family have been identified, including HXT1-HXT17 , SNF3, RGT2, and 
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GAL2 (212). Snf3 and Rgt2 are glucose sensors, which regulate the expression of HXT 
genes but do not transport glucose (213,214). Only HXT1-HXT7 are known to express 
functional hexose transporters (215). HXT1 and HXT3 encode low-affinity glucose 
transporters (212,216). Their expression is induced by high levels of glucose (217). 
HXT2, HXT6, and HXT7 encode high-affinity transporters, while HXT4 encodes 
intermediate-affinity transporter (216). Transcription of HXT2 and HXT4 is induced by 
low levels of glucose (218) and repressed by high levels of glucose (217,219-221). 
HXT6 and HXT7 transcription is also repressed in high glucose (222).   
 The repression of HXT2 and HXT4 under high glucose conditions is mediated by 
the Snf1-Mig1 pathway (211,223,224). Mig1 is a zinc-finger protein that binds to DNA 
and recruits co-repressors Ssn6 and Tup1 to repress gene expression (225). Snf1, the 
yeast homolog of mammalian AMP-activated kinase, is activated under low glucose 
conditions. Active Snf1 phosphorylates Mig1 on multiple serine residues (226-228). 
Phosphorylated Mig1 translocates from the nucleus to the cytoplasm to allow 
expression of glucose-repressible genes, including HXT2 and HXT4 (229). In high 
glucose, both Mig1 and Snf1 are dephosphorylated by the Reg1-Gly7 protein 
phosphatase complex, which allows Mig1 to enter the nucleus and restore glucose 
repression (230,231).  
 In this study, I discovered that VPA decreased expression of hexose transporter 
genes and induced Mig1 nuclear translocation. VPA treated cells exhibited decreased 
expression of HXT2, HXT4, HXT6, and HXT7. The ablation of MIG1 or REG1 alleviated 
VPA-induced inhibition of HXT2 and HXT4 expression. Furthermore, VPA triggered 
Mig1 nuclear translocation under non-repressive conditions. This study shows for the 
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first time that VPA inhibits expression of hexose transporter genes via Mig1. Decreased 
expression of hexose transporter genes may account for VPA-induced G-6-P depletion.  
MATERIALS AND METHODS 
Yeast strains 
 All strains used in this study were in the W303 background. mig1△ and reg1△ 
strains were constructed by gene knockout using KanMX and ble (phleomycin 
resistance gene) cassettes, respectively. The MIG1-GFP:KanMX NRD1-RFP:HghMX 
strain was kindly provided by Dr. Stefan Hohmann from University of Gothenburg, 
Sweden (232).  
Growth media 
Yeast cells were grown at 30°C in synthetic complete (SC) medium, which 
contained glucose (2% w/v) and necessary supplements including adenine (20 mg/liter), 
arginine (20 mg/liter), histidine (20 mg/liter), methionine (20 mg/liter), tryptophan (20 
mg/liter), leucine (60 mg/liter), lysine (200 mg/liter), threonine (300 mg/liter), ammonium 
sulfate (0.2% w/v), inositol-free Difco vitamin mix, and vitamin-free yeast base. VPA (1 
mM) was added separately as indicated.  
Hexokinase activity assay 
 WT cells were grown in SC medium to the mid log phase and treated with 1 mM 
VPA for 3 h. Cells were lysed in lysis buffer (20 mM Tris-HCl pH 7.5, 6 mM MgCl2) by 
vortexing with acid-washed glass beads at 4°C in the presence of 1X protease inhibitor 
and 1X phosphatase inhibitor. Cell extract was mixed with reaction buffer (20 mM Tris-
HCl pH 7.5, 6 mM MgCl2, 1 mM ATP, 0.5 mM NAD+ and 2 mM glucose). Reactions 
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were started by adding 1unit/ml glucose-6-phosphate dehydrogenase. Reaction rates 
were determined by monitoring NADH production at 340 nM in 15 min (233).  
Pyruvate kinase assay 
 WT cells were grown in SC medium to the mid log phase and treated with 1 mM 
VPA for 3 h, then lysed in lysis buffer (20 mM Tris-HCl pH 7.5, 6 mM MgCl2) by 
vortexing with acid-washed glass beads at 4°C in the presence of 1X protease inhibitor 
and 1X phosphatase inhibitor. Cell extract was mixed with reaction buffer (20 mM Tris-
HCl pH 7.5, 6 mM MgCl2, 1 mM ADP, 0.4 mM NADH, 1 unit/mL lactate dehydrogenase 
and 1 mM phosphoenolpyruvate). Reaction rates were determined by monitoring NADH 
consumption at 340 nM for 15 min (233).  
Measurement of intracellular G-6-P levels 
To determine intracellular G-6-P levels, yeast cells were washed twice with ice-
cold dH2O, and lysed in dH2O containing 1X protease inhibitor by vortexing with acid-
washed glass beads at 4°C. Cell extracts were mixed with 1 ml ice cold MeOH:CHCL3 
(2:1), vortexed and stored at -20°C for 2 h. Samples were then mixed with extraction 
solution (50% MeOH, 4 mM tricine pH 5.4) and centrifuged at 18,000 g for 10 min. The 
upper phase was collected and kept on ice. The lower chloroform phase was extracted 
again with extraction solution. Upper phases from both extractions were combined, 
dried with a speedvac, and stored at -80°C. Prior to assay, samples were dissolved in 
dH2O. G-6-P content in samples was measured by the enzyme-coupled fluorescence 
assay developed by Zhu et al. with modification (175).  
Real-time PCR 
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Yeast mRNA was extracted from cells using the RNeasy plus Mini Kit (QIAGEN), 
and was converted to cDNA with a Transcriptor First Strand cDNA Synthesis Kit 
(Roche). RT-PCR was performed using Brilliant III Ultra-Fast SYBR green qPCR master 
mix (Agilent) and MX3000p qPCR System (Agilent). mRNA levels were normalized to 
TCM1 or ALG9 as indicated. 
Fluorescence microscopy 
 MIG1-GFP:KanMX NRD1-RFP:HghMX cells were grown in SC medium to the 
early stationary phase, and treated with 1 mM VPA. Fluorescence microscopy was 
performed using an Olympus BX41 fluorescence microscope. Images were acquired 
using an Olympus Q-Color3 camera operated by QCapture2 software. All pictures were 
taken at 400X at room temperature. 
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Table 4-1. Strains used in this study.  
Strain   Genotype      Source 
W303   MATa his3, leu2, ura3, trp1, ade2   Andoh T. (173) 
mig1∆   MATa his3, leu2, ura3, trp1, ade2, mig1::KanMX  This study 
reg1∆   MATa his3, leu2, ura3, trp1, ade2, reg1::ble  This study 
MIG1-GFP NRD1-RFP MATa his3, leu2, ura3, trp1, ade2,   Hohmann S. (232) 
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Table 4-2. RT-PCR primers used in this study.  
    ________________________________________________________ 
  Gene    Sequence 
  HXT1    TGTCGGTGGTATCACAGTTT 
      CAAGGTGCCTCTCATTTCAC  
 
  HXT2    GTGTCTATTGGGTGGTTCTG 
      GCCTTGGAAGATGGTTGAT 
 
  HXT3    CCCAGACCATCCATTCATTC   
      GGCTTACCAGTGAACAACTC 
  
  HXT4    GGCTGTTTGGTCTTTTCTTAC 
      AGCGTTGTAGTCAGTACCT   
 
  HXT6    CTTTGGAAGAAGTCAACACC 
      CTTATCATCGTGAGCCATTTC 
 
  HXT7    CTTTGGAAGAAGTCAACACC 
      CTTGTCATCGTGAGTCATTTC 
 
  HXK1    TACCTCCTACCCAGCAAGAA 
      AGAGTGGTCTTGACACCAAAG 
 
  HXK2    CTGTGAATACGGTTCCTTCG 
      GTTTGTTGGCCTGGTCTT 
 
  GLK1    CTCAAGCACTTGCCTACTAC 
      CAAGAACATCCCTGAGACAC 
 
  TCM1    CCACGTCACGGTCATTTAG  
      GTCATACCAGCCTTGTAACC 
 
  ALG9    TGGTCTTCTTCCAGGTGAT  
      GGGCGACGATGTCAATAAA 
    ________________________________________________________ 
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RESULTS 
Chronic VPA treatment decreases intracellular G-6-P levels 
 A microarray analysis carried out by my lab member, Shyamala Jadhav, revealed 
upregulation of glycolysis genes after chronic treatment with VPA, suggesting that VPA 
impacts energy metabolism. I conducted a time course study of intracellular G-6-P 
levels in cells exposed to VPA. As seen in Fig. 4-1, after an initial increase at 30 min, G-
6-P levels decreased with chronic exposure to VPA. Hexokinases catalyze the 
synthesis of G-6-P from glucose (234). VPA did not inhibit hexokinases activities in vitro 
(Fig. 4-2), suggesting that VPA does not inhibit G-6-P synthesis. Pyruvate kinase 
catalyzes the irreversible conversion of phosphoenolpyruvate to pyruvate, which is one 
of the rate-limiting and final step of glycolysis (234). Pyruvate kinase activity was not 
affected by VPA (Fig. 4-2). As activities of enzymes involved in G-6-P synthesis and 
glycolysis are not affected by VPA, the intracellular G-6-P depletion may result from 
decreased glucose uptake.   
VPA decreases expression of hexose transporter genes 
 I determined effects of VPA on expression of hexose transporter genes. 
Surprisingly, VPA treatment resulted in significantly decreased mRNA levels of HXT2, 
HXT4, HXT6, and HXT7 (Fig. 4-3). The expression of HXT1 and HXT3, which encode 
low affinity glucose transporters, was not affected by VPA (data not shown). VPA has 
been reported to be inhibitor of histone deacetylase (HDAC), which regulates gene 
expression by deacetylating histones. To determine if changes in transporter gene  
74 
 
 
 
 
 
 
 
 
 
 
Figure 4-1. VPA depletes intracellular glucose 6-phosphate levels. Cells were 
grown in SC medium to the early log phase and treated with 1 mM VPA. Intracellular 
inositol levels were determined as described in “Materials and Methods”. Data shown 
are representative of three independent experiments. Values shown are mean ± SEM. 
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Figure 4-2. VPA does not affect hexokinase (HK) and pyruvate kinase (PK) 
activities in vitro. Yeast cells were grown in SC medium to the early log phase and 
treated with 1 mM VPA. HK and PK activities were determined as described in 
“Materials and Methods”. Values shown are mean ± SEM. Date shown are 
representative of three independent HK assays and two independent PK assays. 
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Figure 4-3. VPA inhibits expression of HXT2, HXT4, HXT6, and HXT7. Yeast cells 
were grown in SC medium to the early log phase and treated with 1 mM VPA. mRNA 
levels of hexose transporter genes were determined by RT-PCR.  
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expression result from HDAC inhibition, we determined mRNA levels of HXT2 and 
HXT4 in yeast cells treated with TSA, a potent HDAC inhibitor. As seen in Fig. 4-4, TSA 
treatment did not inhibit HXT2 and HXT4 expression, suggesting that VPA did not affect 
HXT2 and HXT4 expression by HDAC inhibition.  
VPA-induced decrease in hexose transporter gene expression is Mig1 dependent 
 The expression of HXT2 and HXT4 is repressed by Mig1 (211,223,224). The 
ablation of MIG1 delayed the inhibition of HXT2 and HXT4 expression in VPA-treated 
cells (Fig. 4-5), suggesting that Mig1 mediated the effect of VPA on expression of 
hexose transporter genes. The intracellular localization of Mig1 is determined by its 
phosphorylation status. Under high glucose conditions, Mig1 is dephosphorylated by the 
Reg1-Glc7 complex, which leads to Mig1 nuclear translocation to repress HXT2 and 
HXT4 expression (225,230). Under glucose-limited conditions, Mig1 is phosphorylated 
by Snf1, and therefore excluded from the nucleus to allow expression of HXT2 and 
HXT4 (226). We determined the effect of VPA on Mig1 nucleocytoplasmic distribution in 
MIG1-GFP:KanMX NRD1-RFP:HghMX cells, which express GFP-tagged Mig1 and 
RFP-tagged nuclear protein Nrd1 (232). Surprisingly, VPA triggered Mig1 nuclear 
translocation at the early stationary phase (Fig. 4-6), when glucose was depleted in the 
media. Mig1 nuclear translocation persisted for up to 3 h after VPA treatment. These 
findings suggest that VPA inhibits HXT2 and HXT4 expression by promoting Mig1 
mediated transcription repression.  
VPA-induced repression of hexose transporter gene expression is Mig1 
dependent 
 As discussed above, Mig1 dephosphorylation by the Reg1-Glc7 complex is 
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Figure 4-4. Histone deacetylase inhibition does not inhibit HXT2 or HXT4 
expression. Cells were grown in SC medium to the early log phase and treated with 2 
μM or 10 μM TSA. mRNA levels of hexose transporter genes were determined by RT-
PCR.  
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Figure 4-5. VPA-induced inhibition of HXT2 and HXT4 expression is delayed in 
mig1∆ cells. WT and mig1∆ cells were grown in SC medium to the early log phase and 
treated with 1 mM VPA. mRNA levels of hexose transporter genes were determined by 
RT-PCR.  
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Figure 4-6. VPA triggers Mig1 nuclear translocation under low glucose conditions. 
MIG1-GFP:KanMX NRD1-RFP:HghMX cells were grown in SC medium to the early 
stationary phase and treated with 1 mM VPA. Mig1 intracellular localization was 
determined by fluorescence microscopy.  
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required for Mig1 entry into the nucleus under high glucose conditions. We determined 
HXT2 and HXT4 mRNA1 levels in VPA treated reg1∆ cells. VPA did not inhibit HXT4 
expression in reg1∆ cells (Fig. 4-7). However, deletion of REG1 did not restore HXT2 
mRNA levels in VPA-treated cells (data not shown), which suggested that Mig1 may 
require additional co-factors to repress HXT2 expression. These findings support the 
hypothesis that VPA promotes Mig1 dephosphorylation via the Reg1-Gly7 complex to 
repress expression of hexose transporter genes, and thereby reduces intracellular G-6-
P levels. 
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Figure 4-7. Reg1 is required for VPA-induced inhibition of HXT4 expression. reg1∆ 
cells were grown in SC medium to the early log phase and treated with 1 mM VPA. 
mRNA levels of HXT4 were determined by RT-PCR.  
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DISCUSSION 
 The current study demonstrates for the first time that VPA depletes intracellular 
G-6-P levels. Furthermore, VPA promotes Mig1 mediated transcription repression of 
hexose transporter genes, possibly by activating the Reg1-Glc7 protein phosphatase 
complex. G-6-P plays a central role in energy metabolism. These findings suggest that 
VPA-induced cellular effects, including inositol depletion, increased glycolytic gene 
expression, and increased ethanol production, may result, at least partially, from 
perturbation of G-6-P metabolism. 
 Chronic VPA treatment depleted intracellular G-6-P levels (Fig. 4-1). G-6-P is at 
the branch point of glycolysis, the inositol de novo synthesis pathway, the pentose 
phosphate pathway, and the glycogen synthesis pathway. Therefore, perturbation of G-
6-P metabolism is expected to affect these pathways. Glycolysis and inositol synthesis 
both utilize G-6-P as a substrate. Interestingly, the Km of MIPS for G-6-P (1.18 mM) is 
much higher than that of the glycolytic enzyme phosphoglucoisomerase (0.3 mM), 
which convert G-6-P to fructose 6-phosphate (235,236). These findings suggest that G-
6-P depletion would drive G-6-P flux to glycolysis rather than to inositol synthesis. 
Consistent with this hypothesis, VPA decreases inositol synthesis (60), upregulates 
expression of glycolytic genes, and increases ethanol production (personal 
communication with Shyamala Jadhav and Michael Salsaa). In this light, G-6-P 
depletion may contribute, at least in part, to VPA-induced inositol depletion. 
 VPA decreased mRNA levels of HXT2, HXT4, HXT6, and HXT7 (Fig. 4-3), which 
encode intermediate-affinity and high-affinity glucose transporters that function optimally 
at glucose concentrations of 1% or lower (211). Decreased expression of HXT2 in VPA 
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treated yeast cells was also observed in a microarray study carried out by my lab 
member Shyamala Jadhav. The expression of HXT2, HXT4, HXT6, and HXT7 genes is 
regulated in response to extracellular glucose concentrations (211). Low glucose (0.1%) 
induces the expression of HXT2 and HXT4, while high glucose (4%) represses 
expression of all four genes. The medium used in this study contains 2% glucose. As 
glucose is gradually consumed, the expression of intermediate-affinity and high-affinity 
glucose transporters is required by yeast cells to take up glucose efficiently. VPA-
induced inhibition of HXT2, HXT4, HXT6, and HXT7 may decrease glucose uptake and 
therefore deplete intracellular G-6-P.  
 Expression of HXT2 and HXT4 genes is repressed by the Mig1 repressor under 
high glucose conditions (211).  Deletion of the MIG1 gene delayed inhibition of HXT2 
and HXT4 expression after VPA treatment (Fig. 4-5), suggesting that VPA inhibits 
expression of HXT2 and HXT4 via Mig1. The yeast genome contains a MIG1 homolog, 
MIG2, which has similar but not identical functions in regulating expression of glucose 
repressible genes (225,237). Therefore, Mig2 may repress transcription of HXT genes 
in response to VPA in mig1∆ cells at a slower rate. 
 Mig1 exhibits dual intracellular localization. Under low glucose conditions, Mig1 is 
phosphorylated by Snf1 and localizes in the cytosol (226). In high glucose, Mig1 is 
dephosphorylated by the Reg1-Gly7 protein phosphatase complex, which allows Mig1 
to enter the nucleus and repress gene expression (225,230).  Interestingly, VPA 
triggered Mig1 nuclear localization under low glucose conditions (Fig. 4-6), which was 
consistent with VPA-induced inhibition of HXT2 and HXT4 expression. These findings 
suggest that VPA causes Mig1 dephosphorylation and thereby promotes its 
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nucleocytoplasmic distribution.  Deletion of the REG1 gene abolished the inhibitory 
effect of VPA on HXT4 expression (Fig. 4-7), suggesting that VPA promotes Reg1-Gly7 
mediated dephosphorylation of Mig1. In support of this hypothesis, my previous studies  
have shown that VPA inhibits HXK1 and GLK1 expression in 30 min (Fig. 4-8). 
HXK1, HXK2 and GLK1 encode glucose kinases that convert glucose to G-6-P (238). In 
addition, Hxk2 functions as a transcription regulator, which represses expression of 
HXK1 and GLK1 in response to availability of glucose (239). Similar to Mig1, Hxk2 
shuttles in and out of the nucleus to regulate gene expression (240). Therefore, the 
decrease in HXK1 and GLK1 mRNA levels in VPA treated cells suggests that VPA 
triggers nuclear translocation of Hxk2. The nucleocytoplasmic distribution of Hxk2 is 
determined by the phosphorylation status of the protein. The dephosphorylated Hxk2 is 
imported into the nucleus, while the phosphorylated form is exported from the nucleus 
to the cytoplasm (241). Interestingly, the phosphorylation and dephosphorylation of 
Hxk2 are also carried out by Snf1 kinase and the Reg1-Glc7 protein phosphatase 
complex (241). These findings suggest that VPA-induced inhibition of HXK1 and GLK1 
expression may also result from Reg1-Glc7 mediated Hxk2 dephosphorylation.  
 My study suggests the following model (Fig. 4-9). VPA promotes 
dephosphorylation of Mig1 via the Reg1-Glc7 complex, and triggers the nuclear 
translocation of Mig1. In the nucleus, Mig1 represses expression of hexose transporter 
genes, which leads to decreased glucose uptake. With limited availability of glucose, the 
synthesis of G-6-P decreases accordingly and results in G-6-P depletion. 
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Figure 4-8. VPA decreases HXK1 and GLK1 expression in 30 min. WT cells were 
grown in SC media to the early log phase and treated with 1 mM VPA. mRNA levels of 
HXK1, HXK2 and GLK1  were determined by RT-PCR.  
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Figure 4-9. Model of VPA-induced glucose 6-phosphate depletion. VPA leads to 
dephosphorylation of Mig1 via the Reg1-Glc7 complex. Dephosphorylated Mig1 
translocates to the nucleus and represses HXT2/4 transcription.  Downregulation of 
glucose transporter expression decreases glucose uptake. Limited availability of 
intracellular glucose results in decreased G-6-P synthesis, which contributes, at least in 
part, to G-6-P depletion. 
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CHAPTER 5  FUTURE DIRECTIONS 
 The studies described here identified and characterized novel regulatory 
mechanisms of inositol biosynthesis, both in yeast and mammalian cells. However, 
many questions that arose from these studies await answers. The following discussion 
describes questions that may be developed into research projects for future students. 
1. How does Mck1 regulate MIPS activity in response to VPA? 
 In Chapter 2, I have shown that deletion of MCK1 decreased MIPS activity (Fig. 
2-3). As discussed before, MIPS activity is regulated by phosphorylation (64).  In 
addition, Mck1 has been shown to phosphorylate a protein substrate and therefore 
regulate its activity (242). However, Mck1 did not phosphorylate MIPS in vitro (Fig. 2-5). 
There are at least two possible explanations. First, the phosphorylation of MIPS by 
Mck1 may require co-factors or scaffold proteins that target Mck1 to MIPS. The second 
possibility is that Mck1 does not phosphorylate MIPS directly. Instead, Mck1 regulates a 
down-stream pathway that phosphorylates MIPS. The mechanism whereby Mck1 
regulates MIPS activity remains to be determined.  
 Mck1 has been shown to mediate VPA-caused MIPS inhibition (Fig. 2-4).  
However, it is not clear how VPA regulates Mck1. In mammalian cells, Gsk3 activity is 
regulated at the phosphorylation level by PI3K/Akt pathways (106,107).  It is possible 
that VPA regulates Mck1 by a conserved mechanism in yeast. Further investigation is 
required to characterize the signaling pathway between VPA and Mck1. 
 In addition, the simultaneous deletion of MRK1, MDS1, and YGK3 results in 
increased intracellular inositol levels, suggesting that at least one of these genes 
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downregulates inositol synthesis. It will be interesting to study how these genes affect 
inositol metabolism. 
2. What is the role of inositol pyrophosphate in the regulation of inositol 
synthesis in mammalian cells? 
 As discussed in Chapter 3, IP6K1-KO cells exhibited decreased DNA methylation 
levels at the mIno1 promoter region (Figure 3-3). How does IP6K1 or its product, inositol 
pyrophosphate, regulate DNA methylation? I hypothesize that inositol pyrophosphate 
affects enzymatic activity of DNA methyltransferase. Future work should focus on 
potential links between existing regulatory mechanisms of DNA methylation and 
functions of inositol pyrophosphate. 
 I also showed that IP6K1 negatively regulates mIno1 expression (Fig. 3-2, 3-7). 
IP6K1 has been reported to have direct interaction with chromatin (26), which suggests 
a close association between IP6K1 and DNA. I hypothesize that IP6K1 or its product, 
inositol pyrophosphate, represses mIno1 transcription by inhibiting the assembly of the 
transcription complex. Addressing this hypothesis will benefit the characterization of 
functions of inositol pyrophosphate in the regulation of inositol synthesis. 
3. What is the role of VPA in regulating glucose metabolic flux?  
 Studies have been reported that VPA inhibits inositol synthesis and increases 
glycolysis. G-6-P is the common substrate for both pathways. VPA also depletes 
intracellular G-6-P levels, which is at the branch point of glycolysis, inositol synthesis, 
the pentose phosphate pathway, and the glycogen synthesis pathway. These findings 
suggest that many of the plethora of biochemical effects of VPA may result from 
perturbation of G-6-P metabolism. It is of great importance to determine the effect of 
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VPA on glucose metabolic flux. The elucidation of this question will greatly benefit the 
understanding of the therapeutic mechanism of VPA. 
 Finally, I want to emphasize that we have certainly not finished the exciting 
journey towards the exploration, identification, and characterization of functions of the 
pivotal molecule inositol, and the underlying regulatory mechanisms that control its 
synthesis. It is my privilege if my dissertation sparks new ideas for future students. 
Together, we push science to a new frontier.  
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ABSTRACT 
NOVEL REGULATORY MECHANISMS OF INOSITOL BIOSYNTHESIS IN 
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 Myo-inositol is the precursor of all inositol containing molecules, including inositol 
phosphates, phosphoinositides and glycosylphosphatidylinositols, which are signaling 
molecules involved in many critical cellular functions. Perturbation of inositol metabolism 
has been linked to neurological disorders. Although several widely-used anticonvulsants 
and mood-stabilizing drugs have been shown to exert inositol depletion effects, the 
mechanisms of action of the drugs and the role of inositol in these diseases are not 
understood. Elucidation of the molecular control of inositol synthesis will shed light on 
the pathologies of inositol related illnesses. 
 In Saccharomyces cerevisiae, deletion of the four glycogen synthase kinase-3 
genes, MCK1, MRK1, MDS1, and YGK3, resulted in multiple features of inositol 
depletion. My studies demonstrated that the MCK1 gene is required for normal inositol 
homeostasis. mck1∆ and gsk3∆ (mck1∆mrk1∆mds1∆ygk3∆) cells exhibited similar 
features of inositol depletion. MCK1 ablation led to decreased myo-inositol-3-phosphate 
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synthase (MIPS) activity and a decreased rate of inositol de novo synthesis. This is the 
first demonstration that Mck1 controls inositol synthesis by regulating MIPS activity.  
 While elegant studies have revealed several inositol-regulating mechanisms in 
yeast, very little is known about regulation of inositol synthesis in mammals. My studies 
discovered that IP6K1, an inositol hexakisphosphate kinase that catalyzes the synthesis 
of inositol pyrophosphate, negatively regulates inositol synthesis in mammalian cells. 
Interestingly, IP6K1 preferentially bound to the phospholipid phosphatidic acid, and this 
binding was required for IP6K1 nuclear localization and the transcriptional regulation of 
Isyna1, which encodes mammalian MIPS. This is the first demonstration of the 
molecular control of de novo synthesis of inositol in mammalian cells. 
 VPA depletes intracellular glucose 6-phosphate in yeast cells by an unidentified 
mechanism. My studies discovered that VPA inhibits expression of hexose transporter 
genes HXT2, HXT4, HXT6, and HXT7. Mig1, a DNA-binding transcription repressor that 
translocates to the nucleus to repress gene expression under high glucose conditions, 
is required to inhibit HXT2 and HXT4 expression. Interestingly, VPA triggered Mig1 
nuclear localization under non-repressive conditions. Furthermore, ablation of REG1, 
which regulates Mig1 translocation, reversed VPA-induced inhibition of HXT4 
expression. These findings suggest that VPA may inhibit glucose uptake by activating 
Mig1-mediated repression of hexose transporter genes. 
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